Form 8-K

8-K — RAPID MICRO BIOSYSTEMS, INC.

Accession: 0001104659-26-063936

Filed: 2026-05-19

Period: 2026-05-18

CIK: 0001380106

SIC: 3826 (LABORATORY ANALYTICAL INSTRUMENTS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — tm2614922d1_8k.htm (Primary)

EX-1.1 — EXHIBIT 1.1 (tm2614922d1_ex1-1.htm)

EX-4.1 — EXHIBIT 4.1 (tm2614922d1_ex4-1.htm)

EX-4.2 — EXHIBIT 4.2 (tm2614922d1_ex4-2.htm)

EX-4.3 — EXHIBIT 4.3 (tm2614922d1_ex4-3.htm)

EX-5.1 — EXHIBIT 5.1 (tm2614922d1_ex5-1.htm)

EX-5.2 — EXHIBIT 5.2 (tm2614922d1_ex5-2.htm)

EX-10.1 — EXHIBIT 10.1 (tm2614922d1_ex10-1.htm)

GRAPHIC (tm2614922d1_ex5-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2614922d1_8k.htm · Sequence: 1

false

0001380106

2026-05-18

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

May 18, 2026

RAPID

MICRO BIOSYSTEMS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-40592

20-8121647

(State or other jurisdiction

of incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

25 Hartwell Avenue, Lexington, MA

02421

(Address of principal executive offices)

(Zip Code)

978-349-3200

(Registrant’s telephone number, including

area code)

Not Applicable

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading

Symbols

Name of each exchange on which

registered

Class A Common Stock, $0.01 par value per share

RPID

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company x

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01

Entry into a Material Definitive Agreement.

Underwriting Agreement

On May 18, 2026, Rapid Micro Biosystems, Inc. (the “Company”)

entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Lake Street Capital

Markets LLC, as representatives of the several underwriters named therein (the “Underwriters”) relating to an underwritten

offering (the “Offering”) of (i) 3,581,000 shares (the “Shares”) of the Company’s Class A common

stock, $0.01 par value per share (the “Common Stock”) and accompanying Series A warrants (“Series A Common

Stock Warrants”) to purchase an aggregate of 3,581,000 shares of Class A common stock (or pre-funded warrants in lieu thereof)

and Series B warrants (“Series B Common Stock Warrants”) to purchase an aggregate of 3,581,000 shares of Class A

common stock (or pre-funded warrants in lieu thereof), and, (ii) in lieu of Common Stock to certain investors, pre-funded warrants

to purchase an aggregate of up to 1,463,000 shares of Common Stock (the “Pre-Funded Warrants” and together with the Series A

Common Stock Warrants, and Series B Common Stock Warrants, the “Warrants” and the shares of Common Stock issuable upon

exercise of the warrants, the “Warrant Shares”) and accompanying Series A Common Stock Warrants to purchase an aggregate

of 1,463,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.955 per share and

Series B Common Stock Warrants to purchase an aggregate of 1,463,000 shares of Class A common stock (or pre-funded warrants

in lieu thereof) at an exercise price of $2.340 per share. Each Share was offered and sold together with an accompanying Series A

Common Stock Warrant and a Series B Common Stock Warrant at a combined offering price of $1.955, and each Pre-Funded Warrant was

offered and sold together with an accompanying Series A Common Stock Warrant and a Series B Common Stock Warrant at a combined

offering price of $1.945, which is equal to the combined offering price per share of Common Stock and accompanying Series A Common

Stock Warrant and Series B Common Stock Warrant less the $0.01 exercise price of each Pre-Funded Warrant. The Offering is expected

to close on May 20, 2026, subject to customary closing conditions.

Each Pre-Funded Warrant has an initial exercise price per share of

$0.01, subject to certain adjustments. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all

of the Pre-Funded Warrants are exercised in full. Each Series A Common Stock Warrant has an initial exercise price per share of $1.955,

subject to certain adjustments and each Series B Common Stock Warrant has an initial exercise price per share of $2.340, subject

to certain adjustments. The Series A Common Stock Warrants are exercisable 6 months from the date of issuance and will expire one

year from the date of issuance. The Series B Common Stock Warrants are exercisable 6 months from the date of issuance and will expire

five years from the date of issuance.

Under the Warrants, the Company

may not effect the exercise of any Warrant, and a holder will not be entitled to exercise any portion of any Warrant (i) if immediately

prior to the exercise, holder (together with its affiliates), beneficially own an aggregate number of shares of Common Stock greater than

4.5% or 4.99% or 9.99%, as applicable (the “Maximum Percentage”) of the total number of issued and outstanding shares of Common

Stock of the Company without taking into account any Warrant Shares, or (ii) to the extent that immediately following the exercise,

the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common

Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock, which such percentage may be changed

at the holder’s election to a higher or lower percentage not in excess of 19.99% upon 61 days’ notice to the Company.

The Series A Common Stock

Warrants include certain rights upon “fundamental transactions” as described therein, including the right of the holders thereof

to receive, upon exercise of the Series A Common Stock Warrants following such fundamental transaction, the same amount and kind

of securities, cash or property as the holder would have been entitled to receive upon the occurrence of such fundamental transaction

if it had been, immediately prior to such fundamental transaction, the holder of the number of Warrant Shares issuable upon exercise of

the Series A Common Stock Warrants.

The Series

A Common Stock Warrants also contain a forced exercise provision granting the Company the right, upon the satisfaction of specified conditions,

to require holders to exercise all or any portion of their Series A Common Stock Warrants.

The Series B Common Stock

Warrants include certain rights upon “fundamental transactions” as described therein, including the right of the holders thereof

to receive from the Company or a successor entity the same type or form of consideration (and in the same proportion) that is being offered

and paid to the holders of Common Stock in such fundamental transaction in the amount of the Black Scholes Value (as described in such

Series A Common Stock Warrants) of the unexercised portion of the applicable Series B Common Stock Warrants on the date of the

consummation of such fundamental transaction.

The Series B Common Stock

Warrants also include a participation rights whereby for a period of twelve months from the original issue date, holders of the Series

B Common Stock Warrants have the right to participate in future issuances of the Company’s Class A common stock or Common Stock

equivalents on pro rata basis, up to an aggregate of 25% of such offering, subject to certain conditions.

The Company estimates that

the net proceeds from the Offering will be approximately $8.9 million, after deducting underwriting discounts and commissions and estimated

offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering to fund working capital and other

general corporate purposes.

The Shares and the Warrants were issued pursuant to a shelf registration

statement on Form S-3 (File No. 333-276081), as filed with the U.S. Securities and Exchange Commission (“SEC”) on

December 15, 2023 and declared effective on December 26, 2023 (the “Registration Statement”), and a related prospectus

included in the Registration Statement, as supplemented by a prospectus supplement dated May 18, 2026.

The Underwriting Agreement

contains customary representations, warranties, covenants, indemnification obligations of the Company and the Underwriters, including

for liabilities under the Securities Act of 1933, as amended, and other obligations of the parties. The representations, warranties and

covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely

for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The foregoing

is only a brief description of the terms of the Underwriting Agreement, does not purport to be a complete statement of the rights and

obligations of the parties under the Underwriting Agreement and the transactions contemplated thereby, and is qualified in its entirety

by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

The foregoing is only a brief

description of the terms of the form of Warrants, does not purport to be a complete statement of the rights and obligations of the parties

thereto and the transactions contemplated thereby, and is qualified in its entirety by reference to the form of Pre-Funded Warrant, the

form of Series A Common Stock Warrant and form of Series B Common Stock Warrant that are filed as Exhibit 4.1, Exhibit 4.2

and Exhibit 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

A copy of the legal opinion

of Goodwin Procter LLP, relating to the validity of the shares issued in the Offering is filed as Exhibit 5.1 to this Current Report

on Form 8-K and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement.

Securities Purchase Agreement

On May 18, 2026,

the Company also entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain of the

Company’s directors and officers (the “D&Os”). Pursuant to the Purchase Agreement, the Company agreed to issue

and sell to the D&Os in a registered direct offering 71,607 shares of Common Stock and accompanying Series A Common Stock

Warrants to purchase an aggregate of 71,607 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) with an exercise price

of $1.955 per share and Series B Common Stock warrants to purchase an aggregate of 71,607 shares of Common Stock (or Pre-Funded

Warrants in lieu thereof) with an exercise price of $2.34 per share (the “Concurrent Offering”) for gross proceeds of

approximately $140,000. Each Share was offered and sold together with an accompanying Series A Common Stock Warrant and a

Series B Common Stock Warrant at a combined offering price of $1.955. The terms of the Series A Common Stock Warrants and

Series B Common Stock Warrants sold to investors in the Concurrent Offering are identical to those sold to investors in the

Offering. The Concurrent Offering was made without an underwriter or placement agent. The Company intends to use the net proceeds of

the Concurrent Offering to fund working capital and other general corporate purposes. The Concurrent Offering is anticipated to

close on or about May 20, 2026, and is contingent and conditioned upon consummation of, the Offering, as well as certain other

customary closing conditions in the Purchase Agreement.

The Purchase Agreement contains

customary representations, warranties, and agreements by the Company. The foregoing summary of the Purchase Agreement is qualified in

its entirety by the full text of the Purchase Agreement, which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

The securities in the Concurrent Offering were offered and sold by

the Company pursuant to the Registration Statement, and a related prospectus included in the Registration Statement, as supplemented by

a prospectus supplement dated May 18, 2026.

A copy of the legal opinion

of Goodwin Procter LLP, relating to the validity of the shares issued in the Concurrent Offering, is filed as Exhibit 5.2 to this

Current Report on Form 8-K and is filed with reference to, and is hereby incorporated by reference into, the Registration Statement.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

1.1

Underwriting Agreement, dated as of May 18, 2026, by and among the Company, TD Securities (USA) LLC and Lake Street Capital Markets LLC, as representatives of the several underwriters named therein.

4.1

Form of Pre-Funded Warrant

4.2

Form of Series A Common Stock Warrant

4.3

Form of Series B Common Stock Warrant

5.1

Opinion of Goodwin Procter LLP

5.2

Opinion of Goodwin Procter LLP

10.1

Securities Purchase Agreement, dated as of May 18, 2026, by and between the Company and the purchasers named therein.

23.1

Consent of Goodwin Procter LLP (included in Exhibit 5.1)

23.2

Consent of Goodwin Procter LLP (included in Exhibit 5.2)

104

Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPID MICRO BIOSYSTEMS, INC.

Date: May 19, 2026

By:

/s/ Sean Wirtjes

Sean Wirtjes

Chief Financial Officer

EX-1.1 — EXHIBIT 1.1

EX-1.1

Filename: tm2614922d1_ex1-1.htm · Sequence: 2

Exhibit 1.1

3,581,000 Shares of Common Stock

Pre-Funded Warrants to Purchase 1,463,000 Shares

of Common Stock

Series A Warrants to Purchase 5,044,000

Shares of Common Stock (or Pre-Funded Warrants in lieu thereof)

Series B Warrants to Purchase 5,044,000

Shares of Common Stock (or Pre-Funded Warrants in lieu thereof)

Rapid Micro Biosystems, Inc.

UNDERWRITING AGREEMENT

May 18, 2026

TD Securities

(USA) LLC

Lake Street

Capital Markets, LLC

As Representatives of the several Underwriters

c/o TD Securities (USA) LLC

1 Vanderbilt Avenue

New York, New York 10017

c/o Lake Street Capital Markets, LLC

121 South 8th Street, Suite 1000

Minneapolis, Minnesota 55402

Dear Sirs:

1.            Introductory.

Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the

terms of this Underwriting Agreement (this “Agreement”), to the several underwriters named in Schedule A

hereto (the “Underwriters,” or, each, an “Underwriter”), an aggregate of (a) 3,581,000

shares of Class A common stock, $0.01 par value (the “Common Stock”) of the Company (the “Firm

Stock”), (b) pre-funded warrants of the Company to purchase up to 1,463,000 shares of Common Stock (the “Pre-Funded

Warrants”), (c) accompanying Series A Common Stock warrants to purchase up to 5,044,000 shares of Common Stock

(or pre-funded warrants of the Company to purchase one share of Common Stock in lieu thereof (the “Series A Pre-Funded

Warrants”)) at an exercise price of $1.955 per share (the “Series A Common Warrants”), and

(c) accompanying Series B Common Stock warrants to purchase up to 5,044,000 shares of Common Stock (or pre-funded warrants of

the Company to purchase one share of Common Stock in lieu thereof (together with the “Series B Pre-Funded Warrants”))

at an exercise price of $2.340 per share (the “Series B Common Warrants,” together with Series A Common

Warrants, the “Common Warrants”). The shares of Common Stock issuable upon exercise of the Common Warrants are

herein referred to as the “Common Warrant Shares.” The shares of Common Stock issuable upon exercise of the

Pre-Funded Warrants (including the Series A Pre-Funded Warrants and Series B Pre-Funded Warrants) are herein referred to as

the “Pre-Funded Warrant Shares.” The Firm Stock, Common Warrants, Pre-Funded Warrants, Series A Pre-Funded

Warrants, Series B Pre-Funded Warrants, Common Warrant Shares and Pre-Funded Warrant Shares are hereinafter collectively referred

to as the “Securities.” Each share of the Firm Stock and Pre-Funded Warrant is being sold with one Series A

Common Warrant to purchase one share of Common Stock and one Series B Common Warrant to purchase one share of Common Stock or, in

each case, Pre-Funded Warrants in lieu thereof. TD Securities (USA) LLC (“TD Cowen”) and Lake Street Capital

Markets, LLC (“Lake Street”) are acting as representatives of the several Underwriters and in such capacity

are hereinafter referred to as the “Representatives.”

2.            Representations

and Warranties of the Company. The Company represents and warrants to the several Underwriters, as of the date hereof and as

of each Closing Date (as defined below), and agrees with the several Underwriters, that:

(a)            Registration

Statement. A registration statement of the Company on Form S-3 (File No. 333-276081) (including all amendments thereto,

the “Initial Registration Statement”) registering the offer and sale of the Securities has been filed with the

Securities and Exchange Commission (the “Commission”). The Initial Registration Statement and any post-effective

amendment thereto, each in the form heretofore delivered to you, and, excluding exhibits thereto, to you for each of the other Underwriters,

have been declared effective by the Commission in such form and meet the requirements of the Securities Act of 1933, as amended (the “Securities

Act”), and the rules and regulations of the Commission thereunder (the “Rules and Regulations”).

Other than (i) the Initial Registration Statement, (ii) a registration statement, if any, increasing the size of the offering

filed pursuant to Rule 462(b) under the Securities Act and the Rules and Regulations (a “Rule 462(b) Registration

Statement”), (iii) the Prospectus (as defined below) contemplated by this Agreement to be filed pursuant to Rule 424(b) of

the Rules and Regulations in accordance with Section 4(a) hereof and (iv) any Issuer Free Writing Prospectus (as defined

below), no other document with respect to the offer or sale of the Securities has heretofore been filed with the Commission. No stop order

suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration

Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been initiated

or threatened by the Commission. The Initial Registration Statement including all exhibits thereto and including the information contained

in the Prospectus filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations and deemed by virtue of

Rules 430A or 430B under the Securities Act to be part of the Initial Registration Statement at the time it became effective is hereinafter

collectively called the “Registration Statement.” If the Company has filed a Rule 462(b) Registration

Statement, then any reference herein to the term “Registration Statement” shall be deemed to include such Rule 462 Registration

Statement. The base prospectus included in the Initial Registration Statement at the time of effectiveness thereof, as supplemented by

the final prospectus supplement relating to the offer and sale of the Securities, in the form filed pursuant to and within the time limits

described in Rule 424(b) under the Rules and Regulations, is hereinafter called the “Prospectus.”

Any reference herein to the Registration Statement or the Prospectus shall be deemed to refer to and include the documents incorporated

by reference therein. Any reference to any amendment or supplement to the Prospectus shall be deemed to refer to and include any documents

filed after the date of the Prospectus under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

and incorporated by reference in such Prospectus, as the case may be. Any reference to (i) the Registration Statement shall be deemed

to refer to and include the annual report of the last completed fiscal year of the Company on Form 10-K filed under Section 13(a) or

15(d) of the Exchange Act prior to the date hereof and (ii) the effective date of such Registration Statement shall be deemed

to refer to and include the date such Registration Statement became effective and, if later, the date such Form 10-K was so filed.

Any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the Company

filed pursuant to Section 13(a) or 15(d) of the Exchange Act after the date of this Agreement that is incorporated by reference

in the Registration Statement.

(b)            General

Disclosure Package. As of the Applicable Time (as defined below) and as of the Closing Date or the Option Closing Date (as defined

below), as the case may be, neither (i) the General Use Free Writing Prospectus(es) (as defined below) issued at or prior to the

Applicable Time, the Pricing Prospectus (as defined below), and the information included on Schedule C hereto, all considered together

(collectively, the “General Disclosure Package”), (ii) any individual Limited Use Free Writing Prospectus

(as defined below), (iii) the bona fide electronic roadshow (as defined in Rule 433(h)(5) of the Rules and Regulations);

nor (iv) any individual Written Testing-the-Waters Communication (as defined below), when considered together with the General Disclosure

Package, included or will include any untrue statement of a material fact or omitted or will omit to state a material fact necessary in

order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however,

that the Company makes no representations or warranties as to information contained in or omitted from the Pricing Prospectus or any Issuer

Free Writing Prospectus (as defined below), in reliance upon, and in conformity with, written information furnished to the Company through

the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree

is limited to the Underwriters’ Information (as defined in Section 18). As used in this paragraph (b) and elsewhere in

this Agreement:

“Applicable Time”

means 9:00 pm, New York time, on the date of this Agreement or such other time as agreed to by the Company and the Representatives.

“Pricing Prospectus”

means the base prospectus filed as part of the Registration Statement in the form in which it has most recently been filed with the Commission

on or prior to the date of this Agreement, as amended and supplemented immediately prior to the Applicable Time, including any document

incorporated by reference therein and any prospectus supplement deemed to be a part thereof.

“Issuer Free Writing

Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the Rules and Regulations

relating to the Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form

retained in the Company’s records pursuant to Rule 433(g) of the Rules and Regulations.

“General Use Free

Writing Prospectus” means any Issuer Free Writing Prospectus that is identified on Schedule B to this Agreement.

“Limited Use Free

Writing Prospectus” means any Issuer Free Writing Prospectus that is not a General Use Free Writing Prospectus.

“Written Testing-the-Waters

Communication” means any Testing-the-Waters Communication (as defined below) that is a written communication within the

meaning of Rule 405 of the Rules and Regulations.

Stop Orders; No Material Misstatements. No order preventing or suspending the use of any Issuer Free Writing Prospectus or the Prospectus

relating to the proposed offering of the Securities has been issued by the Commission, and no proceeding for that purpose or pursuant

to Section 8A of the Securities Act has been instituted or threatened by the Commission.

(d)            Registration

Statement and Prospectus Contents. At the respective times, the Registration Statement and any amendments thereto became or become

effective as to the Underwriters and at each Closing Date, the Registration Statement and any amendments thereto conformed and will conform

in all material respects to the requirements of the Securities Act and the Rules and Regulations and did not and will not contain

any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements

therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement

thereto was issued and at each Closing Date, conformed and will conform in all material respects to the requirements of the Securities

Act and the Rules and Regulations and did not and will not contain an untrue statement of a material fact or omit to state a material

fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;

provided, however, that the foregoing representations and warranties in this paragraph (d) shall not apply to information

contained in or omitted from the Registration Statement or the Prospectus, or any amendment or supplement thereto, in reliance upon, and

in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically

for inclusion therein, which information the parties hereto agree is limited to the Underwriters’ Information.

(e)            Issuer

Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the completion

of the public offer and sale of the Securities or until any earlier date that the Company notified or notifies the Representatives as

described in Section 4(f), did not, does not and will not include any information that conflicted, conflicts or will conflict with

the information contained in the Registration Statement, Pricing Prospectus or the Prospectus, including any document incorporated by

reference therein and any prospectus supplement deemed to be a part thereof that has not been superseded or modified, or included or would

include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary

in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, provided,

however, that the foregoing representations and warranties in this paragraph (e) shall not apply to information contained

in or omitted from such Issuer Free Writing Prospectus, the Registration Statement or the Prospectus, or any amendment or supplement thereto,

in reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of

any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters’ Information.

(f)            Documents

Incorporated by Reference. The documents incorporated, or deemed to be incorporated, by reference in the Prospectus, when they were

filed with the Commission, conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable,

and the rules and regulations of the Commission thereunder and none of such documents contained any untrue statement of a material

fact or omitted to state any material fact required to be stated therein, or necessary to make the statements therein, in the light of

the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the

Prospectus, when such documents are filed with Commission will conform in all material respects to the requirements of the Securities

Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and will not contain any untrue

statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein,

in the light of the circumstances under which they were made, not misleading.

(g)            Distribution

of Offering Materials. The Company has not distributed and will not distribute any offering material in connection with the offering

and sale of the Securities other than the Prospectus and other materials, if any, permitted under the Securities Act and consistent with

Section 4(c) below. The Company will file with the Commission all Issuer Free Writing Prospectuses (other than a “road

show” as described in Rule 433(d)(8) of the Rules and Regulations) in the time and manner required under Rules 163(b)(2) and

433(d) of the Rules and Regulations.

(h)            Emerging

Growth Company. From the first date on which the Company engaged directly or through any person authorized to act on its behalf in

any Testing-the-Waters Communications in reliance on Section 5(d) of the Securities Act through the date hereof, the Company

has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging

Growth Company”).

(i)            Not

an Ineligible Issuer. At the time of filing the Initial Registration Statement, any Rule 462(b) Registration Statement and

any post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an “ineligible

issuer,” as defined in Rule 405 of the Rules and Regulations.

(j)            Testing

the Waters Communications. The Company (a) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters

Communications with the consent of the Representatives with entities that are qualified institutional buyers within the meaning of Rule 144A

under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and

(b) has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications. The Company reconfirms

that the Representatives have been authorized to act on its behalf in undertaking Testing-the-Waters Communications. The Company has not

distributed any Written Testing-the-Waters Communications. “Testing-the-Waters Communication” means any oral

or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act or Rule 163B

of the Rules and Regulations.

(k)            Organization

and Good Standing. The Company and each of its subsidiaries have been duly organized and are validly existing and in good standing

under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction

in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and

have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged,

except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate,

have a material adverse effect on the business, properties, management, financial position, stockholders’ equity, results of operations

or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement

(a “Material Adverse Effect”). The Company does not own or control, directly or indirectly, any corporation,

association or other entity other than the subsidiaries listed in Exhibit 21 to the Company’s Annual Report on Form 10-K

for the year ended December 31, 2025.

(l)            Underwriting

Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(m)          The

Securities. The Firm Stock to be issued and sold by the Company to the Underwriters hereunder has been duly and validly authorized

and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid and non-assessable

and will conform in all material respects to the descriptions thereof in the Registration Statement, the General Disclosure Package and

the Prospectus; and the issuance of the Firm Stock is not subject to any preemptive or similar rights. The Common Warrants and Pre-Funded

Warrants have been duly and validly authorized by the Company, and when executed and delivered by the Company, including in the case of

the Series A Pre-Funded Warrants and Series B Pre-Funded Warrants, upon the exercise of the Common Warrants, will be valid and

binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may

be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies

of creditors or by general equitable principles, and will conform in all material respects to the descriptions thereof in the Registration

Statement, the General Disclosure Package and the Prospectus. The Common Warrant Shares and Pre-Funded Warrant Shares have been duly and

validly authorized and reserved for issuance upon exercise of the Common Warrants and Pre-Funded Warrants, respectively, in a number sufficient

to meet the current exercise requirements. The Common Warrant Shares and Pre-Funded Warrant Shares, when issued and delivered upon exercise

of the Common Warrants and Pre-Funded Warrants, respectively, and in accordance therewith, will be duly and validly issued, fully paid

and non-assessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the General Disclosure

Package and the Prospectus; and the issuance of the Common Warrant Shares and Pre-Funded Warrant Shares is not subject to any preemptive

or similar rights.

(n)            Capitalization.

The Company has an authorized capitalization as is set forth in the Registration Statement, the General Disclosure Package and the Prospectus

under the heading “Capitalization.” All the outstanding shares of capital stock of the Company have been duly and validly

authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive or similar rights that have not been

duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the General Disclosure Package

and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights that have not been duly waived

or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other

equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any

kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities

or any such rights, warrants or options; all outstanding shares of capital stock of the Company conform, and the Securities, when they

have been delivered and paid for in accordance with this Agreement, will conform, in all material respects to the description thereof

contained in the Registration Statement, the General Disclosure Package and the Prospectus; and all the outstanding shares of capital

stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized

and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of any lien, charge,

encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.

(o)            No

Registration Rights. No person has the right to require the Company or any of its subsidiaries to register any securities for sale

under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities,

except for such rights as have been duly waived.

(p)            No

Restrictions on Subsidiaries. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or

other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on

such subsidiary’s capital stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary

from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the

Company.

(q)            No

Material Adverse Change. Subsequent to the respective dates as of which information

is given in the Registration Statement, the General Disclosure Package and the Prospectus, (i) there has not been any change

in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding

in, and the grant of options and awards, including restricted stock, under existing equity incentive plans described in, the Registration

Statement, the General Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries,

or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock,

or any material adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties,

management, financial position, stockholders’ equity, results of operations or prospects of the Company and its subsidiaries taken

as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in

the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation,

direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any

of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken

as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance

or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise

disclosed in the Registration Statement, the General Disclosure Package and the Prospectus.

(r)            Independent

Accountants. PricewaterhouseCoopers LLP, who has certified certain financial statements of the Company and its subsidiaries, is an

independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations

adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.

(s)            Financial

Statements. The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries

included in or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus comply in all

material respects with the applicable requirements of the Securities Act and present fairly in all material respects the financial position

of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their

cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles

(“GAAP”) in the United States applied on a consistent basis throughout the periods covered thereby, except in

the case of unaudited financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes permitted

by applicable rules of the Commission; and any supporting schedules included in or incorporated by reference in the Registration

Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the information required to be stated

therein; and the other financial information included in or incorporated by reference in the Registration Statement, the General Disclosure

Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents

fairly in all material respects, on the basis stated therein, the information shown thereby. There are no “non-GAAP financial measures”

(as such term is defined by the rules and regulations of the Commission) required to comply with Regulation G of the Exchange Act

and Item 10 of Regulation S-K of the Securities Act, to the extent applicable in the Registration Statement, the General Disclosure Package

and the Prospectus.

(t)            XBRL.

The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly

presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and

guidelines applicable thereto.

(u)            Stock

Options. With respect to the stock options (the “Stock Options”) granted pursuant to the stock-based

compensation plans of the Company and its subsidiaries (the “Company Stock Plans”), (i) each Stock Option

intended to qualify as an “incentive stock option” under Section 422 of the Code so qualifies, (ii) each grant of

a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by

all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and

authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award

agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in

accordance with the terms of the Company Stock Plans and all applicable laws and regulatory rules or requirements, and (iv) each

such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company.

(v)            No

Violation or Default. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or by-laws

or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would

constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage,

deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which

the Company or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject;

or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental

or regulatory authority having jurisdiction over the Company and its subsidiaries, except, in the case of clauses (ii) and (iii) above,

for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse

Effect.

(w)            No

Conflicts. The execution, delivery and performance of this Agreement, the Common Warrants and the Pre-Funded Warrants

by the Company, the issuance and sale of the Securities and the consummation of the transactions contemplated by this Agreement and the

Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default

under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance

upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan

agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of

its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii) result

in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries

or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator

or governmental or regulatory authority having jurisdiction over the Company, except, in the case of clauses (i) and (iii) above,

for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably

be expected to have a Material Adverse Effect.

(x)            No

Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator

or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the

Common Warrants or the Pre-Funded Warrants, the issuance and sale of the Securities and the consummation of the transactions contemplated

by this Agreement, except for the registration of the Securities under the Securities Act and such consents, approvals, authorizations,

orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (“FINRA”)

and under applicable state securities laws in connection with the purchase and distribution of the Securities by the Underwriters.

(y)            Legal

Proceedings. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, there

are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”)

pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries

is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could

reasonably be expected to have a Material Adverse Effect; no such Actions are threatened or, to the knowledge of the Company, contemplated

by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending Actions that are required

under the Securities Act to be described in the Registration Statement, the General Disclosure Package or the Prospectus that are not

so described in the Registration Statement, the General Disclosure Package and the Prospectus and (ii) there are no statutes, regulations

or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described

in the Registration Statement, the General Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration

Statement or described in the Registration Statement, the General Disclosure Package and the Prospectus.

(z)            Title

to Real and Personal Property. The Company and its subsidiaries have good and marketable title in fee simple (in the case of real

property) to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective

businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections

of title except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company

and its subsidiaries or (ii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(aa)      Licenses

and Permits. The Company and its subsidiaries possess all licenses, sub-licenses, certificates, certifications, permits

and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign

governmental or regulatory authorities or national standards bodies that are necessary for the ownership or lease of their respective

properties or the conduct of their respective businesses as described in each of the Registration Statement, the General Disclosure Package

and the Prospectus, except where the failure to possess or make the same would not, whether individually or in the aggregate, reasonably

be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement, the General Disclosure Package

and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such

license, sub-license, certificate, certification, permit or authorization or has any reason to believe that any such license, sub-license,

certificate, permit or authorization will not be renewed in the ordinary course except where such revocation or modifications would not,

whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(bb)      No

Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or,

to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance

by, or dispute with, the employees of any of its or its subsidiaries’ principal suppliers, contractors or customers, in each case,

except as would not reasonably be expected to have a Material Adverse Effect.

(cc)      Taxes. The

Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed

through the date hereof except where such failure to pay taxes or file such returns would not, individually or in the aggregate, have

a Material Adverse Effect; and except as otherwise disclosed in the Registration Statement, the General Disclosure Package or the Prospectus,

there is no tax deficiency that has been, or could reasonably be expected to be, asserted by a governmental authority against the Company

or any of its subsidiaries or any of their respective properties or assets except as would not, individually or in the aggregate, have

a Material Adverse Effect.

(dd)      Investment

Company Act. The Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds

thereof as described in the Registration Statement, the General Disclosure Package and the Prospectus, will not be required to register

as an “investment company” or an entity “controlled” by an “investment company” within the meaning

of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the

“Investment Company Act”).

(ee)      Insurance. The

Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business

interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by companies

engaged in the same or similar business and which the Company believes are adequate to protect the Company and its subsidiaries and their

respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such

insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any

reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar

coverage at comparable cost from similar insurers as may be necessary to continue its business.

(ff)      No

Stabilization. Neither the Company nor any of its subsidiaries or, to the knowledge of the Company, affiliates has taken,

directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation

of the price of any security of the Company.

(gg)      Margin

Rules. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company as described

in each of the Registration Statement, the General Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board

of Governors of the Federal Reserve System or any other regulation of such Board of Governors.

(hh)      No

Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on

the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries,

on the other, that is required by the Securities Act to be described in each of the Registration Statement, the General Disclosure Package

and the Prospectus and that is not so described in such documents.

(ii)            Forward-Looking

Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E

of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the General Disclosure Package or the

Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

(jj)      Statistical

and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical

and market-related data included in each of the Registration Statement, the General Disclosure Package and the Prospectus is not based

on or derived from sources that are reliable and accurate in all material respects.

(kk)      Sarbanes-Oxley

Act. There is and, since the effectiveness of the Registration Statement, there has been no failure on the part of the Company or,

to the knowledge of the Company, any of the Company’s directors or officers, in their capacities as such, to comply in all material

respects with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection

therewith, including Section 402 related to loans.

(ll)      No

Unlawful Payments. Neither the Company nor any of its subsidiaries or affiliates nor any director, officer or employee

of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate, representative or other person associated

with or acting on behalf of the Company or any of its subsidiaries or affiliates has (i) used any corporate funds for any unlawful

contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance

of an offer, promise or authorization of any direct or indirect unlawful payment or benefit, including the giving or receipt of money,

property, gifts or anything else of value, to any foreign or domestic government official or employee, including of any government-owned

or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of

the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any

provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention

on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act

2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested

or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence

payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries and affiliates have conducted their

businesses in compliance with applicable anti-corruption laws and have instituted, maintain and enforce, and will continue to maintain

and enforce policies and procedures reasonably designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption

laws and with the representations and warranties contained herein. Neither the Company nor any of its subsidiaries will use, directly

or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving

of money, or anything else of value, to any person in violation of any applicable anti-corruption laws.

(mm)      Compliance

with Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance

with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting

Act of 1970, as amended, the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate

Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the applicable money laundering statutes of all jurisdictions

where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules,

regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering

Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator

involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the

Company, threatened.

(nn)      No

Conflicts with Sanctions Laws. Neither the Company nor any of its subsidiaries, directors, officers or employees, nor,

to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its

subsidiaries is, or is owned or controlled by one or more persons that are, currently the subject or the target of any sanctions administered

or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the

Treasury or the U.S. Department of State and including, without limitation, the designation as a “specially designated national”

or “blocked person”), the United Nations Security Council, the European Union, His Majesty’s Treasury or other relevant

sanctions authority (collectively, “Sanctions”). Neither the Company nor any of its subsidiaries, directors,

officers or employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf

of the Company or any of its subsidiaries is, nor is owned or controlled by one or more persons that are, located, organized or resident

in a country or territory that is the subject or target of Sanctions, including, without limitation, the so-called Donetsk People’s

Republic, so-called Luhansk People’s Republic or any other Covered Region of Ukraine identified pursuant to Executive Order 14065,

the Crimea region of Ukraine, the non-government controlled areas of the Zaporizhzhia and Kherson Regions, Cuba, Iran, North Korea

and Syria (each, a “Sanctioned Country”). The Company will not directly or indirectly use the proceeds of the

offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner

or other person or entity (i) to fund or facilitate any activities of or business with any person or in any country or territory

that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities

of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any

person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years,

the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in, and will not engage in, any dealings

or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with

any Sanctioned Country.

(oo)            Accounting

Controls. The Company and its subsidiaries maintain systems of “internal control over financial reporting”

(as defined in Rule 13a-15(f) of the Exchange Act) that have been designed to comply with the requirements of the Exchange Act

applicable to the Company and have been designed by, or under the supervision of, their respective principal executive and principal financial

officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and

the preparation of financial statements for external purposes in accordance with GAAP. The Company and its subsidiaries maintain internal

accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s

general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in

conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s

general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable

intervals and appropriate action is taken with respect to any differences. Based on the Company’s most recent evaluation of its

internal controls over financial reporting, there are no material weaknesses in the Company’s internal controls. The Company’s

auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies

and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are

reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

(ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s

internal controls over financial reporting.

(pp)      Disclosure

Controls. The Company and its subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined

in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to

ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded,

processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls

and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate

to allow timely decisions regarding required disclosure.

(qq)      Certain

Environmental Matters. (i) The Company and its subsidiaries (x) are in compliance with all, and have not violated any, applicable

federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders

and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural

resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”);

(y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations

or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received notice

of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, applicable Environmental

Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants

or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) there

are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of

each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have

a Material Adverse Effect; and (iii) except as described in the Registration Statement, the General Disclosure Package and the Prospectus,

(x) there is no proceeding that is pending, or that is known to be contemplated, against the Company or any of its subsidiaries under

any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed

no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries are not aware of any facts or issues

regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or

toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a Material Adverse Effect, and (z) none

of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws.

(rr)      Intellectual

Property. (i) The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, all inventions

(including any “subject inventions” developed with government funding as described in clause (ii) below), patents, patent

applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source

indicators, copyrights and copyrightable works, know-how, trade secrets, systems, procedures, proprietary or confidential information

and all other worldwide intellectual property, industrial property and proprietary rights (collectively, “Intellectual Property”)

used or proposed to be used in the current and proposed conduct of their respective businesses; (ii) as contemplated under the Bayh

Dole Act and its implementing regulations, the Company has timely submitted notices of election to retain title to any material subject

invention the Company developed using government funding; (iii) to the knowledge of the Company, the Company’s and its subsidiaries’

conduct of their respective businesses does not infringe, misappropriate or otherwise violate any intellectual property of any person

except those that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; (iv) the

Company and its subsidiaries have not received any written notice of any claim relating to Intellectual Property and, to the knowledge

of the Company, no such claims have been threatened, except any such notice of claim or threatened claim that would not reasonably be

expected, individually or in the aggregate, to have a Material Adverse Effect; (v) to the knowledge of the Company, the Intellectual

Property of the Company and its subsidiaries is valid and enforceable and is not being infringed, misappropriated or otherwise violated

by any person in any respect that would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; (vi) the

Company and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property

has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect; and (vii) the Company and

its subsidiaries have taken commercially reasonable steps to protect, maintain and safeguard the Intellectual Property owned by them,

including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements by their employees

and contractors, and, to the Company’s knowledge, no employee or contractor of the Company is in or has been in violation in a material

respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,

non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such

violation relates to such employee’s employment with the Company.

(ss)      Listing.

The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of

the Exchange Act. The Common Stock is registered pursuant to Section 12(b) or Section 12(g) of the Exchange Act and

is listed on the Nasdaq, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the

registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification

that the Commission or Nasdaq is contemplating terminating such registration or listing. All of the Firm Stock, the Common Warrant Shares

and Pre-Funded Warrant Shares that have been or may be sold under this Agreement have been approved for listing on the Nasdaq, subject

to official notice of issuance; the Company has taken all necessary actions to ensure that, upon and at all times after the Nasdaq shall

have approved the Firm Stock, the Common Warrant Shares and Pre-Funded Warrant Shares for listing, it will be in compliance with all applicable

corporate governance requirements set forth in the Nasdaq’s listing rules that are then in effect.

(tt)      No

Broker’s Fees. Except pursuant to this Agreement, neither the Company nor any of its subsidiaries is a party to

any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any

of them or any Underwriter for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of

the Securities.

(uu)      Cybersecurity;

Data Protection.

(i)            Except,

in each case, as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and

its subsidiaries comply and have at all times complied with applicable privacy, data security and data protection laws and regulations,

contractual obligations, applicable industry guidelines and codes of conduct including, to the extent applicable, the Payment Card Industry

Data Security Standard and Company policies applicable to the Company’s and its subsidiaries’ collection, handling, usage,

disclosure and storage of all personally identifiable data (“Personal Data”) (collectively, the “Privacy

Requirements”).

(ii)            The

Company and its subsidiaries have policies and procedures in place in accordance in all material respects with applicable Privacy Requirements

and takes appropriate steps which are reasonably designed to comply in all material respects with such policies and procedures.

(iii)            To

the extent required under applicable Privacy Requirements, the Company and its subsidiaries have required and do require third parties

to which they provide any Personal Data to maintain the privacy and security of such Personal Data, including by contractually requiring

such third parties to protect such Personal Data from unauthorized access by and/or disclosure to any unauthorized third parties, except

where a failure to do so would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Except

as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect, neither the Company nor any of

its subsidiaries has experienced any security incident breaches, violations, or outages that has compromised the privacy and/or security

of any Personal Data and/or the information technology assets and equipment, computers, systems, networks, hardware, software, websites,

applications, and databases (collectively, “IT Systems”) through which any such Personal Data is collected or

processed or on which the Personal Data is stored, nor has there been any unauthorized uses of the same, except for those that have been

remedied without material costs or liability or the duty to notify any other person, nor any incidents under internal review or investigations

relating to the same.

(iv)            Neither

the Company nor any of its subsidiaries has received written notice asserting a violation by the Company or any of its subsidiaries of

any of the Privacy Requirements. Neither the Company nor any of its subsidiaries is (i) currently conducting or paying for, in whole

or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Requirements; or (ii) a party to any

order, decree, or agreement that imposes any obligation or liability by any governmental or regulatory authority under any Privacy Requirements.

(v)            Except

as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect, the Company’s and its subsidiaries’

IT Systems are adequate for, and operate and perform in all respects as required in connection with, the operation of the business of

the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs,

malware and other corruptants. The Company has implemented and maintained commercially reasonable controls, policies, procedures, and

safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security

of all IT Systems and Personal Data used in connection with its businesses.

(vv)      Compliance

with ERISA. (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security

Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group”

(defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14)

of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of

the Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”)

has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations,

including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA

or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative

exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA,

no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning

of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected

to be, in “at risk status” (within the meaning of Section 303(i) of ERISA) and no Plan that is a “multiemployer

plan” within the meaning of Section 4001(a)(3) of ERISA is in “endangered status” or “critical status”

(within the meaning of Sections 304 and 305 of ERISA); (v) the fair market value of the assets of each Plan exceeds the present value

of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable

event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is

reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code has received

a favorable determination letter, or is entitled to rely on an opinion letter, from the Internal Revenue Service, and to the knowledge

of the Company, nothing has occurred, whether by action or by failure to act, which would reasonably be expected to cause the loss of

such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur,

any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation,

in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan” within the meaning of Section 4001(a)(3) of

ERISA); and (ix) none of the following events has occurred or is reasonably expected to occur: (A) a material increase in the

aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal

year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company’s and its

Controlled Group affiliates’ most recently completed fiscal year; or (B) a material increase in the Company and its subsidiaries’

“accumulated post-retirement benefit obligations” (within the meaning of Accounting Standards Codification Topic 715-60) compared

to the amount of such obligations in the Company and its subsidiaries’ most recently completed fiscal year, except in each case

with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate,

reasonably be expected to have a Material Adverse Effect.

(ww)      Regulatory

Compliance. Except as would not, singly or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company

has not received any U.S. Food and Drug Administration Form 483, written notice of adverse finding, warning letter, untitled letter

or other written correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting

non-compliance with the Federal Food, Drug, and Cosmetic Act or comparable foreign laws. Neither the Company, nor any of its subsidiaries

nor, to the Company’s knowledge, any of their respective employees, officers, directors, or agents has been excluded, suspended,

debarred or disqualified from participation in any U.S. federal health care program or human clinical research or, to the knowledge of

the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably be expected

to result in debarment, disqualification, suspension, or exclusion.

(xx)            Export

and Import Laws. For the past five (5) years, each of the Company and its subsidiaries, and, to the Company’s knowledge,

each of their affiliates and any director, officer, agent or employee of, or other person, while acting on behalf of the Company, has

acted in compliance in all material respects with applicable Export and Import Laws (as defined below). There are no claims, complaints,

charges, investigations or proceedings pending or expected or, to the knowledge of the Company, threatened between the Company or any

of its subsidiaries and any governmental authority under any Export or Import Laws. The term “Export and Import Laws”

means the Arms Export Control Act, the International Traffic in Arms Regulations, the Export Administration Act of 1979, as amended, the

Export Administration Regulations, and all other laws and regulations of the United States government regulating the provision of services

to non-U.S. parties or the export and import of articles or information from and to the United States of America, and all similar laws

and regulations of any foreign government regulating the provision of services to parties not of the foreign country or the export and

import of articles and information from and to the foreign country to parties not of the foreign country.

(yy)      No

Associated Persons; FINRA Matters. Neither the Company nor, to the knowledge of the Company, any of its affiliates (within the meaning

of FINRA Rule 5121(f)(1)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated

person (within the meaning of Article I, Section 1(ee) of the By-laws of FINRA) of, any member firm of FINRA.

(zz)      No

Acquisitions or Dispositions. Except as are described in the Registration Statement, the General Disclosure Package and the Prospectus,

there are no contracts, letters of intent, term sheets, agreement, arrangements or understandings with respect to the direct or indirect

acquisition or disposition by the Company of material interests in real or personal property.

(aaa)      Outbound

Investments. Neither the Company nor any of its subsidiaries is a “covered foreign person”, as that term is defined in

31 C.F.R. § 850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly,

in a “covered activity”, as that term is defined in 31 C.F.R. § 850.208 (“Covered Activity”).

The Company does not have any joint ventures that engages in or plans to engage in any Covered Activity. The Company also does not, directly

or indirectly, hold a board seat on, have a voting or equity interest in, or have any contractual power to direct or cause the direction

of the management or policies of any person or persons that engages or plans to engage in any Covered Activity.

Any certificate signed by or on behalf of the

Company and delivered to the Representatives or to counsel for the Underwriters shall be deemed to be a representation and warranty by

the Company to each Underwriter as to the matters covered thereby.

3.            Purchase,

Sale and Delivery of Offered Securities. On the basis of the representations, warranties and agreements herein contained, but

subject to the terms and conditions herein set forth, the Company agrees to sell to the Underwriters, and the Underwriters agree, severally

and not jointly, to purchase from the Company the respective numbers of shares of Firm Stock, Common Warrants and Pre-Funded Warrants

set forth opposite the names of the Underwriters in Schedule A hereto.

The purchase price to be paid

by the Underwriters to the Company for (i) the Firm Stock and accompanying Common Warrants will be $1.8377 per share and accompanying

Common Warrant (the “Common Stock Purchase Price”) and (ii) Pre-Funded Warrants and the accompanying Common

Warrants will be $1.8377 per Pre-Funded Warrant and accompanying Common Warrant (the “Pre-Funded Warrant Purchase Price”).

The Company will deliver the

Firm Stock to the Representatives for the respective accounts of the several Underwriters, through the facilities of The Depository Trust

Company, in each such case, issued in such names and in such denominations as the Representatives may direct by notice in writing to the

Company given at or prior to 12:00 Noon, New York time, on the first (1st) full business day preceding the Closing Date against payment

of the aggregate Common Stock Purchase Price therefor by wire transfer in federal (same day) funds to an account at a bank specified by

the Company payable to the order of the Company. Time shall be of the essence, and delivery at the time and place specified pursuant to

this Agreement is a further condition of the obligations of each Underwriter hereunder. The time and date of the delivery and closing

shall be at 10:00 A.M., New York time, on May 20, 2026, in accordance with Rule 15c6-1 of the Exchange Act. The time and date

of such payment and delivery are herein referred to as the “Closing Date.” The Closing Date and the location

of delivery of, and the form of payment for, the Firm Stock may be varied by agreement between the Company and the Representatives.

The Company will deliver,

or cause to be delivered, to the purchasers thereof the Common Warrants and Pre-Funded Warrants in accordance with the Underwriters’

instructions to be sold by them, in each case at the Closing Date, against payment of the aggregate Common Stock Purchase Price and Pre-Funded

Warrant Purchase Price, as applicable, by wire transfer in federal (same day) funds to an account at a bank specified by the Company payable

to the order of the Company. The Common Warrants and Pre-Funded Warrants will be made available for inspection by the Representatives

on the business day prior to the Closing Date.

Notwithstanding the foregoing,

the Company and the Representatives shall instruct the purchasers of the Pre-Funded Warrants and accompanying Common Warrants to make

payment for such Pre-Funded Warrants and accompanying Common Warrants on the Closing Date to the Company by wire transfer in immediately

available funds to the account specified by the Company for the aggregate Pre-Funded Warrant Purchase Price, in lieu of payment by the

Underwriters for such Pre-Funded Warrants and accompanying Common Warrants, and the Company shall deliver the Pre-Funded Warrants and

accompanying Common Warrants to such purchasers on such date in definitive paper form against such payment, in lieu of the Company’s

obligation to deliver such Pre-Funded Warrants and accompanying Common Warrants to the Representatives; provided that, the Underwriters

shall withhold $0.11730 per Pre-Funded Warrant and accompanying Common Warrant as an offset against the payment owed by the Underwriters

to the Company for the Firm Stock as payment for the underwriting discounts and commissions in respect of the Pre-Funded Warrants and

accompanying Common Warrants. In the event that any purchaser of the Pre-Funded Warrants and accompanying Common Warrants fails to make

payment to the Company for all or part of the Pre-Funded Warrants and accompanying Common Warrants on the Closing Date, the Representatives

shall either (i) make payment to the Company for such Pre-Funded Warrants and accompanying Common Warrants specified in this Section 3

or (ii) elect, by written notice to the Company, to receive shares of Common Stock at the Common Stock Purchase Price specified in

this Section 3 in lieu of all or a portion of such Pre-Funded Warrants and accompanying Common Warrants contemplated to be sold under

this Agreement.

The several Underwriters propose

to offer the Securities for sale upon the terms and conditions set forth in the Prospectus. The Company acknowledges and agrees that the

Underwriters may offer and sell Securities to or through any affiliate of an Underwriter.

4.            Further

Agreements Of The Company. The Company agrees with the several Underwriters:

(a)            Required

Filings; Amendments or Supplements; Notice to the Representative. To prepare the Rule 462(b) Registration Statement, if

necessary, in a form approved by the Representatives and file such Rule 462(b) Registration Statement with the Commission by

10:00 P.M., New York time, on the date hereof, and the Company shall at the time of filing either pay to the Commission the filing fee

for the Rule 462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under

the Rules and Regulations; to prepare the Prospectus in a form approved by the Representatives containing information previously

omitted at the time of effectiveness of the Registration Statement in reliance on Rules 430A or 430B of the Rules and Regulations

and to file such Prospectus pursuant to Rule 424(b) of the Rules and Regulations not later than the second business (2nd)

day following the execution and delivery of this Agreement or, if applicable, such earlier time as may be required by the Securities Act;

to notify the Representatives immediately of the Company’s intention to file or prepare any supplement or amendment to the Registration

Statement or to the Prospectus and to make no amendment or supplement to the Registration Statement, the General Disclosure Package or

to the Prospectus to which the Representatives shall reasonably object by notice to the Company after a reasonable period to review; to

advise the Representatives, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has

been filed or becomes effective or any supplement to the General Disclosure Package or the Prospectus or any amended Prospectus or any

Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication has been filed and to furnish the Underwriters with copies

thereof; to file promptly all material required to be filed by the Company with the Commission pursuant to Rules 433(d) or 163(b)(2) of

the Rules and Regulations, as the case may be; to file promptly all reports and any definitive proxy or information statements required

to be filed by the Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent

to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of

the Rules and Regulations) is required in connection with the offering or sale of the Securities; to advise the Representatives,

promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending

the use of any Issuer Free Writing Prospectus, the Prospectus or any Written Testing-the-Waters Communication, of the suspension of the

qualification of the Securities for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such

purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement, the General Disclosure Package

or the Prospectus or for additional information including, but not limited to, any request for information concerning any Testing-the-Waters

Communication; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Issuer Free

Writing Prospectus or the Prospectus or suspending any such qualification, and promptly to use its best efforts to obtain the withdrawal

of such order.

(b)            Emerging

Growth Company. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any

time prior to the later of (a) the completion of the distribution of the Firm Stock, Common Warrants and Pre-Funded Warrants within

the meaning of the Securities Act and (b) completion of the Lock-Up Period (as defined below). If at any time following the distribution

of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters

Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary

in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company

will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication

to eliminate or correct such untrue statement or omission.

Free Writing Prospectus. The Company represents and agrees that, unless it obtains the prior consent of the Representatives, and each

Underwriter represents and agrees that, unless it obtains the prior consent of the Company and the Representatives, it has not made and

will not make any offer relating to the Securities that would constitute a “free writing prospectus” as defined in Rule 405

of the Rules and Regulations unless the prior written consent of the Representatives has been received (each, a “Permitted

Free Writing Prospectus”); provided that the prior written consent of the Representatives hereto shall be deemed to have

been given in respect of the Issuer Free Writing Prospectuses included in Schedule B hereto. The Company represents that it has treated

and agrees that it will treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, comply with the requirements

of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free Writing Prospectus, including the requirements

relating to timely filing with the Commission, legending and record keeping and will not take any action that would result in an Underwriter

or the Company being required to file with the Commission pursuant to Rule 433(d) of the Rules and Regulations a free writing

prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.

(d)            Ongoing

Compliance. If at any time prior to the date when a prospectus relating to the Securities is required to be delivered (or in lieu

thereof, the notice referred to in Rule 173(a) under the Securities Act) any event occurs or condition exists as a result of

which the Prospectus as then amended or supplemented would include any untrue statement of a material fact, or omit to state any material

fact necessary to make the statements therein, in the light of the circumstances under which they were made when the Prospectus is delivered

(or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations), not misleading, or if it is necessary

at any time to amend or supplement the Registration Statement or the Prospectus or to file under the Exchange Act any document incorporated

by reference in the Prospectus to comply with the Securities Act or the Exchange Act, that the Company will promptly notify the Representatives

thereof and upon their request will prepare an appropriate amendment or supplement or upon their request make an appropriate filing pursuant

to Section 13 or 14 of the Exchange Act in form and substance satisfactory to the Representatives which will correct such statement

or omission or effect such compliance and will use its reasonable best efforts to have any amendment to the Registration Statement declared

effective as soon as possible. The Company will furnish without charge to each Underwriter and to any dealer in securities as many copies

as the Representatives may from time to time reasonably request of such amendment or supplement. In case any Underwriter is required to

deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) relating

to the Securities, the Company upon the request of the Representatives will prepare promptly an amended or supplemented Prospectus as

may be necessary to permit compliance with the requirements of Section 10(a)(3) of the Securities Act and deliver to such Underwriter

as many copies as such Underwriter may request of such amended or supplemented Prospectus complying with Section 10(a)(3) of

the Securities Act.

(e)            Amendment

to General Disclosure Package. If the General Disclosure Package is being used to solicit offers to buy the Securities at a time when

the Prospectus is not yet available to prospective purchasers and any event shall occur as a result of which, in the judgment of the Company

or in the reasonable opinion of the Underwriters, it becomes necessary to amend or supplement the General Disclosure Package in order

to make the statements therein, in the light of the circumstances then prevailing, not misleading, or to make the statements therein not

conflict with the information contained or incorporated by reference in the Registration Statement then on file and not superseded or

modified, or if it is necessary at any time to amend or supplement the General Disclosure Package to comply with any law, the Company

promptly will either (i) prepare, file with the Commission (if required) and furnish to the Underwriters and any dealers an appropriate

amendment or supplement to the General Disclosure Package or (ii) prepare and file with the Commission an appropriate filing under

the Exchange Act which shall be incorporated by reference in the General Disclosure Package so that the General Disclosure Package as

so amended or supplemented will not, in the light of the circumstances then prevailing, be misleading or conflict with the Registration

Statement then on file, or so that the General Disclosure Package will comply with law.

(f)            Amendment

to Issuer Free Writing Prospectus. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs

an event or development as a result of which such Issuer Free Writing Prospectus conflicted or will conflict with the information contained

in the Registration Statement, Pricing Prospectus or Prospectus, including any document incorporated by reference therein and any prospectus

supplement deemed to be a part thereof, and not superseded or modified or included or would include an untrue statement of a material

fact or omitted or would omit to state a material fact required to be stated therein or necessary in order to make the statements therein,

in the light of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly notified or will promptly

notify the Representatives so that any use of the Issuer Free Writing Prospectus may cease until it is amended or supplemented and the

Company has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate

or correct such conflict, untrue statement or omission. The foregoing sentence does not apply to statements in or omissions from any Issuer

Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company through the Representatives

by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters’

Information.

(g)            Delivery

of Registration Statement. To the extent not available on the Commission’s Electronic Data Gathering, Analysis and Retrieval

system or any successor system (“EDGAR”), upon the request of the Representatives, to furnish promptly to the

Representatives and to counsel for the Underwriters a signed copy of the Registration Statement as originally filed with the Commission,

and of each amendment thereto filed with the Commission, including all consents and exhibits filed therewith.

(h)            Delivery

of Copies. Upon request of the Representatives, to the extent not available on EDGAR, to deliver promptly to the Representatives in

New York City such number of the following documents as the Representatives shall reasonably request: (i) conformed copies of the

Registration Statement as originally filed with the Commission (in each case excluding exhibits), (ii) any Issuer Free Writing Prospectus,

(iii) the Prospectus (the delivery of the documents referred to in clauses (i), (ii) and (iii) of this paragraph (h) to

be made not later than 10:00 A.M., New York time, on the business day following the execution and delivery of this Agreement), (iv) conformed

copies of any amendment to the Registration Statement (excluding exhibits), (v) any amendment or supplement to the General Disclosure

Package or the Prospectus, and (vi) any document incorporated by reference in the General Disclosure Package or the Prospectus (excluding

exhibits thereto) (the delivery of the documents referred to in clauses (iv), (v) and (vi) of this paragraph (h) to be

made not later than 10:00 A.M., New York City time, on the business day following the date of such document, amendment or supplement).

(i)            Earnings

Statement. To make generally available to the Company’s stockholders as soon as practicable, but in any event not later than

sixteen (16) months after the effective date of the Registration Statement (as defined in Rule 158(c) of the Rules and

Regulations), an earnings statement of the Company and its consolidated subsidiaries (which need not be audited) complying with Section 11(a) of

the Securities Act (including, at the option of the Company, Rule 158).

(j)            Blue

Sky Compliance. To take promptly from time to time such actions as the Representatives may reasonably request to qualify the Securities

for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Representatives may reasonably

designate and to continue such qualifications in effect, and to comply with such laws, for so long as required to permit the offer and

sale of the Securities in such jurisdictions; provided that the Company and its subsidiaries shall not be obligated to (i) qualify

as foreign corporations in any jurisdiction in which they are not so qualified, (ii) file a general consent to service of process

in any jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.

(k)            Reports.

Upon request, during the period of five (5) years from the date hereof, to deliver to each of the Underwriters, (i) as soon

as they are available, copies of all reports or other communications (financial or other) furnished to the Company’s stockholders,

and (ii) as soon as they are available, copies of any reports and financial statements furnished or filed with the Commission or

any national securities exchange on which the Firm Stock, the Common Warrant Shares and Pre-Funded Warrant Shares are listed. However,

so long as the Company is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act

and is timely filing reports on EDGAR, it is not required to furnish such reports or statements to the Underwriters.

(l)            Lock-Up.

During the period commencing on and including the date hereof and ending on and including the 60th day following the date of

this Agreement, (the “Lock-Up Period”) the Company will not, without the prior written consent of the Representatives

(which consent may be withheld at the sole discretion of the Representatives), directly or indirectly offer, sell (including, without

limitation, any short sale), assign, transfer, pledge, contract to sell, establish an open “put equivalent position” within

the meaning of Rule 16a-1(h) under the Exchange Act, or otherwise dispose of, or announce the offering of, or submit or file

any registration statement under the Securities Act in respect of, any Common Stock, options, rights or warrants to acquire Common Stock

or securities exchangeable or exercisable for or convertible into Common Stock (other than is contemplated by this Agreement with respect

to the Securities) or publicly announce any intention to do any of the foregoing; provided, however, that the Company may (i) issue

Common Stock, restricted stock unit and options to purchase Common Stock, shares of Common Stock underlying restricted stock units and

options granted and other securities, each pursuant to any director or employee incentive award plan, stock ownership plan or dividend

reinvestment plan of the Company in effect on the date hereof and described in the General Disclosure Package; (ii) issue Common

Stock pursuant to the conversion of securities or the exercise of warrants, which securities or warrants are outstanding on the date hereof

and described in the General Disclosure Package or the Common Warrants or Pre-Funded Warrants; (iii) issue shares of Common Stock

pursuant to the Sales Agreement, dated December 15, 2023 (the “ATM”), by and between the Company and Cowen and

Company, LLC after forty-five (45) days following the date of this Agreement, provided further, that in the event the closing price of

the Company’s Common Stock the Exchange exceeds $3.85, the Company may issue shares of Common Stock in the ATM; (iv) adopt

a new equity incentive plan, and file a registration statement on Form S-8 under the Securities Act to register the offer and sale

of securities to be issued pursuant to such new equity incentive plan, and issue securities pursuant to such new equity incentive plan

(including, without limitation, the issuance of shares of Common Stock upon the exercise of options or other securities issued pursuant

to such new equity incentive plan), provided that (A) such new equity incentive plan satisfies the transaction requirements

of General Instruction A.1 of Form S-8 under the Securities Act and (B) this clause (iv) shall not be available unless

each recipient if such person is an officer or director of the Company, of shares of Common Stock, or securities exchangeable or exercisable

for or convertible into Common Stock, pursuant to such new equity incentive plan shall be contractually prohibited from selling, offering,

disposing of or otherwise transferring any such shares or securities during the remainder of the Lock-Up Period; (v) facilitate the

transfer of shares of Common Stock under a trading plan pursuant to Rule 10b5-1 under the Exchange Act (a “Trading Plan”)

that is existing on the date hereof which has been provided to the Representatives or their legal counsel, (vi) facilitate the establishment

of a trading plan on behalf of a shareholder, officer or director of the Company pursuant to Rule 10b5-1 under the Exchange Act for

the transfer of Common Stock, provided that (A) such plan does not provide for the transfer of Common Stock during the Lock-Up Period

and (B) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company

regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common

Stock may be made under such plan during the Lock-Up Period and (vii) effect the offering and sale of common stock pursuant to the

concurrent registered direct offering described in each of the Registration Statement, the General Disclosure Package and the Prospectus.

The Company will cause each person and entity listed in Schedule D to furnish to the Representatives, prior to the Closing Date,

a “lock-up” agreement, substantially in the form of Exhibit I hereto. In addition, the Company will direct the

transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such “lock-up”

agreements. During the period commencing on and including the date hereof and ending on and including the earlier of (x) 180th

day following the date of this Agreement and (y) the date that none of the Common Warrants are outstanding, the Company shall be

prohibited from effecting or entering into an agreement to effect any “Variable Rate Transaction.” The term “Variable

Rate Transaction” shall mean a transaction in which the Company (i) issues or sells any debt or equity securities that are

convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at

a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the

shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise

or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon

the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common

Stock or (ii) enters into any agreement, including, but not limited to, an equity line of credit, whereby the Company may sell securities

at a future determined price. For the avoidance of doubt, the issuance of a security which is subject to customary anti-dilution protections,

including where the conversion, exercise or exchange price is subject to adjustment as a result of stock splits, reverse stock splits

and other similar recapitalization or reclassification events, shall not be deemed to be a “Variable Rate Transaction.” For

the further avoidance of doubt, “Variable Rate Transaction” does not include the issuance of revenue bonds or other straight

debt instruments with no equity or equity-linked components, traditional term loans or credit facilities that do not include equity or

equity-linked conversion features, or the ATM.

(m)            Delivery

of SEC Correspondence. To supply the Underwriters with copies of all correspondence to and from, and all documents issued to and by,

the Commission in connection with the registration of the Securities under the Securities Act or any of the Registration Statement, or

the Prospectus, or any amendment or supplement thereto or document incorporated by reference therein.

(n)            Press

Releases. Prior to the Closing Date, not to issue any press release or other communication directly or indirectly or hold any press

conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects (except

for routine oral marketing communications in the ordinary course of business and consistent with the past practices of the Company and

of which the Representatives are notified), without the prior consent of the Representatives, unless in the judgment of the Company and

its counsel, and after notification to the Representatives, such press release or communication is required by law.

(o)            Compliance

with Regulation M. Until the Underwriters shall have notified the Company of the completion of the resale of the Securities, that

the Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation M under the

Exchange Act) not to, either alone or with one or more other persons, bid for or purchase, for any account in which it or any of its affiliated

purchasers has a beneficial interest, any Securities, or attempt to induce any person to purchase any Securities; and not to, and to use

its reasonable best efforts to cause its affiliated purchasers not to, make bids or purchase for the purpose of creating actual, or apparent,

active trading in or of raising the price of the Securities.

(p)            Registrar,

Transfer Agent and Warrant Agent. To maintain, at its expense, a registrar and transfer agent for the Firm Stock, Common Warrant Shares

and Pre-Funded Warrant Shares, and a warrant agent, which shall initially be the Company, for the Common Warrants and Pre-Funded Warrants.

(q)            Use

of Proceeds. To apply the net proceeds from the sale of the Securities as set forth in the Registration Statement, the General Disclosure

Package and the Prospectus under the heading “Use of Proceeds,” and except as disclosed in the General Disclosure Package,

the Company does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to

any affiliate of any Underwriter.

(r)            Exchange

Listing. To use its reasonable best efforts to list, subject to notice of issuance, the Firm Stock, the Common Warrant Shares and

Pre-Funded Warrant Shares on the Nasdaq Capital Market (the “Exchange”).

(s)            Performance

of Covenants and Satisfaction of Conditions. To use its reasonable best efforts to do and perform all things required to be done or

performed under this Agreement by the Company prior to each Closing Date and to satisfy all conditions precedent to the delivery of the

Firm Stock, Common Warrants and the Pre-Funded Warrants.

(t)            Reservation

of Pre-Funded Warrant Shares and Common Warrant Shares. The Company shall, at all times while any Pre-Funded Warrants or Common Warrants

are outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Shares,

solely for the purpose of enabling it to issue Pre-Funded Warrant Shares and Common Warrant Shares upon exercise of such warrants, the

number of Pre-Funded Warrant Shares and Common Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding

Pre-Funded Warrants and Common Warrants.

5.            Payment

of Expenses. The Company agrees to pay, or reimburse if paid by any Underwriter, whether or not the transactions contemplated

hereby are consummated or this Agreement is terminated: (a) the costs incident to the authorization, issuance, sale, preparation

and delivery of the Securities and any taxes payable in that connection; (b) the costs incident to the registration of the Securities

under the Securities Act; (c) the costs incident to the preparation, printing and distribution of the Registration Statement, any

Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any amendments, supplements and exhibits thereto or any

document incorporated by reference therein and the costs of printing, reproducing and distributing the “Agreement Among Underwriters”

between the Representatives and the Underwriters, the Master Selected Dealers’ Agreement, the Underwriters’ Questionnaire,

this Agreement and any closing documents by mail, telex or other means of communications; (d) the fees and expenses (including related

fees and expenses of counsel for the Underwriters) incurred in connection with determining the compliance of this offering with FINRA’s

rules and securing any required review by FINRA of the terms of the sale of the Securities and any filings made with FINRA (the “FINRA

Expenses”); (e) any applicable listing or other fees; (f) the fees and expenses (including the reasonable and documented

fees and expenses of counsel to the Underwriters related thereto) of qualifying the Securities under the securities laws of the several

jurisdictions as provided in Section 4(j) and of preparing, printing and distributing wrappers, Blue Sky Memoranda and Legal

Investment Surveys; (g) the cost of preparing and printing stock certificates; (h) all fees and expenses of the registrar and

transfer agent of the Firm Stock, Common Warrant Shares and Pre-Funded Warrant Shares; (i) the fees, disbursements and expenses of

counsel to the Underwriters(inclusive of the FINRA Expenses) up to an aggregate of $100,000; (j) costs and expenses of the Company

relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities,

including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated

with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations

with the prior approval of the Company, travel and lodging expenses of the officers of the Company and such consultants, including the

cost of any aircraft chartered in connection with the road show; (k) the costs of reproducing and distributing each of the Common

Warrants and Pre-Funded Warrants; and (l) all other costs and expenses incident to the offering of the Securities or the performance

of the obligations of the Company under this Agreement (including, without limitation, the fees and expenses of the Company’s counsel

and the Company’s independent accountants); provided that, except to the extent otherwise provided in this Section 5

and in Sections 9 and 10, the Underwriters shall pay their own costs and expenses, including the fees and expenses of their counsel not

contemplated herein, any transfer taxes on the resale of any Securities by them and the expenses of advertising any offering of the Securities

made by the Underwriters.

6.            Conditions

of Underwriters’ Obligations. The respective obligations of the several Underwriters hereunder are subject to the accuracy,

when made and as of the Applicable Time and on each Closing Date, of the representations and warranties of the Company contained herein,

to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the

Company of its obligations hereunder, and to each of the following additional terms and conditions:

(a)            Registration

Compliance; No Stop Orders. The Registration Statement has become effective under the Securities Act, and no stop order suspending

the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of the Prospectus or any Permitted

Free Writing Prospectus or any part thereof shall have been issued and no proceedings for that purpose or pursuant to Section 8A

under the Securities Act shall have been initiated or threatened by the Commission, and all requests for additional information on the

part of the Commission (to be included or incorporated by reference in the Registration Statement or the Prospectus or otherwise) shall

have been complied with to the reasonable satisfaction of the Representatives; the Rule 462(b) Registration Statement, if any,

each Issuer Free Writing Prospectus and the Prospectus shall have been filed with, the Commission within the applicable time period prescribed

for such filing by, and in compliance with, the Rules and Regulations and in accordance with Section 4(a), and the Rule 462(b) Registration

Statement, if any, shall have become effective immediately upon its filing with the Commission; and FINRA shall have raised no unresolved

objection to the fairness and reasonableness of the terms of this Agreement or the transactions contemplated hereby.

(b)            No

Material Misstatements. None of the Underwriters shall have discovered and disclosed to the Company on or prior to such Closing Date

that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the opinion of

counsel for the Underwriters, is material or omits to state any fact which, in the opinion of such counsel, is material and is required

to be stated therein or is necessary to make the statements therein not misleading, or that the General Disclosure Package, any Issuer

Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which, in the opinion

of such counsel, is material or omits to state any fact which, in the opinion of such counsel, is material and is necessary in order to

make the statements, in the light of the circumstances in which they were made, not misleading.

Proceedings. All corporate proceedings incident to the authorization, form and validity of each of this Agreement, the Securities,

the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus and the Prospectus and the transactions

contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Underwriters and the Company shall have

furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon such matters.

(d)            Opinion

and 10b-5 Statement of Counsel for the Company. Goodwin Procter LLP shall have furnished to the Representatives such counsel’s

written opinion and 10b-5 statement, as counsel to the Company, addressed to the Underwriters and dated such Closing Date, in form and

substance reasonably satisfactory to the Representatives.

(e)            Opinion

of Intellectual Property Counsel for the Company. Goodwin Procter LLP shall have furnished to the Representatives such counsel’s

written opinion, as intellectual property counsel to the Company, addressed to the Underwriters and dated such Closing Date, in form and

substance reasonably satisfactory to the Representatives.

(f)            Opinion

and 10b-5 Statement of Counsel for the Underwriters. The Representatives shall have received from Covington & Burling LLP,

counsel for the Underwriters, such opinion or opinions and 10b-5 statement, dated such Closing Date, with respect to such matters as the

Underwriters may reasonably require, and the Company shall have furnished to such counsel such documents as they request for enabling

them to pass upon such matters.

(g)            Comfort

Letter. At the time of the execution of this Agreement, the Representatives shall have received from PricewaterhouseCoopers LLP a

letter, addressed to the Underwriters, executed and dated such date, in form and substance satisfactory to the Representatives (i) confirming

that they are an independent registered accounting firm with respect to the Company and its subsidiaries within the meaning of the Securities

Act and the Rules and Regulations and PCAOB and (ii) stating the conclusions and findings of such firm, of the type ordinarily

included in accountants’ “comfort letters” to underwriters, with respect to the financial statements and certain financial

information contained or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus.

(h)            Bring

Down Comfort. On the effective date of any post-effective amendment to the Registration Statement and on such Closing Date, the Representatives

shall have received a letter (the “bring-down letter”) from PricewaterhouseCoopers LLP addressed to the Underwriters

and dated such Closing Date confirming, as of the date of such bring-down letter (or, with respect to matters involving changes or developments

since the respective dates as of which specified financial information is given in the General Disclosure Package and the Prospectus,

as the case may be, as of a date not more than three (3) business days prior to the date of the bring-down letter), the conclusions

and findings of such firm, of the type ordinarily included in accountants’ “comfort letters” to underwriters, with respect

to the financial information and other matters covered by its letter delivered to the Representatives concurrently with the execution

of this Agreement pursuant to paragraph (g) of this Section 6.

(i)            Officers’

Certificate. The Company shall have furnished to the Representatives a certificate, dated such Closing Date, of the President and

Chief Executive Officer and Chief Financial Officer of the Company stating in their respective capacities as officers of the Company on

behalf of the Company that (i) no stop order suspending the effectiveness of the Registration Statement (including, for avoidance

of doubt, any Rule 462(b) Registration Statement), or any post-effective amendment thereto, shall be in effect and no proceedings

for such purpose shall have been instituted or, to their knowledge, threatened by the Commission, (ii) for the period from and including

the date of this Agreement through and including such Closing Date, there has not occurred any Material Adverse Effect, (iii) to

their knowledge, after reasonable investigation, as of such Closing Date, the representations and warranties of the Company in this Agreement

are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied

hereunder at or prior to such Closing Date, and (iv) there has not been, subsequent to the date of the most recent audited financial

statements included or incorporated by reference in the General Disclosure Package, any Material Adverse Effect in the financial position

or results of operations of the Company, or any change or development that would, singularly or in the aggregate, reasonably be expected

to have a Material Adverse Effect, except as set forth in the General Disclosure Package and the Prospectus.

(j)            No

Material Adverse Effect. Since the date of the latest audited financial statements included in the General Disclosure Package or incorporated

by reference in the General Disclosure Package as of the date hereof, (i) neither the Company nor any of its subsidiaries shall have

sustained any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance,

or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the General Disclosure Package,

and (ii) there shall not have been any change in the capital stock or long-term debt of the Company or any of its subsidiaries, or

any change, or any development involving a prospective change, in or affecting the business, general affairs, management, financial position,

stockholders’ equity or results of operations of the Company and its subsidiaries, otherwise than as set forth in the General Disclosure

Package, the effect of which, in any such case described in clause (i) or (ii) of this paragraph (j), is, in the judgment of

the Representatives, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery of the Securities

on the terms and in the manner contemplated in the General Disclosure Package.

(k)            No

Legal Impediment to Issuance. No action shall have been taken and no law, statute, rule, regulation or order shall have been enacted,

adopted or issued by any governmental or regulatory agency or body which would prevent the issuance or sale of the Securities; and no

injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued

which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially materially and adversely

affect the business or operations of the Company.

(l)            Market

Conditions. Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following: (i) other

than in connection with the offering and sale of the Securities, trading in any of the securities of the Company shall have been suspended

or materially limited by the Commission or the Exchange, or trading in securities generally on the New York Stock Exchange, Nasdaq Global

Select Market, Nasdaq Global Market, the Exchange, or the NYSE MKT LLC, or in the over-the-counter market, or trading in any securities

of the Company on any exchange or in the over-the-counter market, shall have been suspended or materially limited, or minimum or maximum

prices or maximum range for prices shall have been established on any such exchange or such market by the Commission, by such exchange

or market or by any other regulatory body or governmental authority having jurisdiction, (ii) a banking moratorium shall have been

declared by Federal or state authorities or a material disruption has occurred in commercial banking or securities settlement or clearance

services in the United States, (iii) the United States shall have become engaged in hostilities, or the subject of an act of terrorism,

or there shall have been an outbreak of or escalation in hostilities involving the United States, or there shall have been a declaration

of a national emergency or war by the United States or (iv) there shall have occurred such a material adverse change in general economic,

political or financial conditions (or the effect of international conditions on the financial markets in the United States shall be such)

as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the sale or delivery of the Securities

on the terms and in the manner contemplated in the General Disclosure Package and the Prospectus.

(m)            Exchange

Listing. The Company shall have filed a Notification: Listing of Additional Shares with the Exchange in respect of the Firm Stock,

the Common Warrant Shares and the Pre-Funded Warrant Shares and shall have received no objection thereto from the Exchange.

(n)            Good

Standing. The Representatives shall have received on and as of such Closing Date satisfactory evidence of the good standing of the

Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other

jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the

appropriate governmental authorities of such jurisdictions.

(o)            Lock

Up Agreements. The Representatives shall have received the written agreements, substantially in the form of Exhibit I

hereto, of the persons listed in Schedule D to this Agreement.

(p)            Secretary’s

Certificate. The Company shall have furnished to the Representatives a Secretary’s Certificate of the Company, in form and substance

reasonably satisfactory to counsel for the Underwriters and customary for the type of offering contemplated by this Agreement.

(q)            Chief

Financial Officer Certificate. The Company shall have furnished to the Representatives a certificate, dated such Closing Date, of

its Chief Financial Officer, substantially in the form of Exhibit II hereto.

(r)            Additional

Documents. On or prior to such Closing Date, the Company shall have furnished to the Representatives such further certificates and

documents as the Representatives may reasonably request.

(s)            Form of

Pre-Funded Warrants and Common Warrants. On or prior to such Closing Date, evidence of the Pre-Funded Warrants and Common Warrants

shall be delivered to those persons and entities as directed by the Representatives in the form and substance reasonably acceptable the

Representatives, including to reflect such names and in such denomination as the Representatives directed pursuant to Section 3.

All opinions, letters, evidence

and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if

they are in form and substance reasonably satisfactory to counsel for the Underwriters.

7.            Indemnification

and Contribution.

(a)            Indemnification

of Underwriters by the Company. The Company shall indemnify and hold harmless: each Underwriter, its affiliates, directors, officers,

managers, members, employees, representatives and agents and each person, if any, who controls any Underwriter within the meaning of Section 15

of the Securities Act or Section 20 of the Exchange Act (collectively the “Underwriter Indemnified Parties,”

and each an “Underwriter Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever

(or any action, investigation or proceeding in respect thereof), joint or several, to which such Underwriter Indemnified Party may become

subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding

arises out of or is based upon (A) any untrue statement or alleged untrue statement of a material fact contained in any Written Testing-the-Waters

Communication, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) of

the Rules and Regulations, the Registration Statement, the Prospectus, or in any amendment or supplement thereto, in any document

incorporated by reference therein, or in any materials or information provided to investors by, or with the approval of, the Company in

connection with the marketing of the offering of the Securities, including any roadshow or investor presentations made to investors by

the Company (whether in person or electronically) (“Marketing Materials”), or (B) the omission or alleged

omission to state in any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to

Rule 433(d) of the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement

thereto or document incorporated by reference therein, or in any Marketing Materials, a material fact required to be stated therein or

necessary to make the statements therein not misleading; and shall reimburse each Underwriter Indemnified Party promptly upon demand for

any reasonable and documented legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection with

investigating, or preparing to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred

in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are

incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim,

damage, expense or liability arises out of or is based upon an untrue statement or alleged untrue statement in, or omission or alleged

omission from the Registration Statement or the Prospectus, or any such amendment or supplement thereto, any Issuer Free Writing Prospectus

or any Marketing Materials made in reliance upon and in conformity with written information furnished to the Company through the Representatives

by or on behalf of any Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriters’

Information.

The indemnity agreement in this Section 7(a) is

not exclusive and is in addition to each other liability which the Company might have under this Agreement or otherwise, and shall not

limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to any Underwriter Indemnified

Party.

(b)            Indemnification

of Company by the Underwriters. Each Underwriter, severally and not jointly, shall indemnify and hold harmless the Company and its

directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of

Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the “Company Indemnified Parties”

and each a “Company Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever (or

any action, investigation or proceeding in respect thereof), joint or several, to which such Company Indemnified Party may become subject,

under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises

out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any Issuer Free Writing

Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) of the Rules and

Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto, or (ii) the omission or alleged

omission to state in any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to

Rule 433(d) of the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement

thereto, a material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only

to the extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity

with written information furnished to the Company through the Representatives by or on behalf of that Underwriter specifically for use

therein, which information the parties hereto agree is limited to the Underwriters’ Information, and shall reimburse the Company

Indemnified Parties for any reasonable and documented legal or other expenses reasonably incurred by such party in connection with investigating

or preparing to defend or defending against or appearing as third party witness in connection with any such loss, claim, damage, liability,

action, investigation or proceeding, as such fees and expenses are incurred. This indemnity agreement is not exclusive and will be in

addition to any liability which the Underwriters might otherwise have and shall not limit any rights or remedies which may otherwise be

available under this Agreement, at law or in equity to the Company Indemnified Parties.

after receipt by an indemnified party under this Section 7 of notice of the commencement of any action, the indemnified party shall,

if a claim in respect thereof is to be made against an indemnifying party under this Section 7, notify such indemnifying party in

writing of the commencement of that action; provided, however, that the failure to notify the indemnifying party shall not relieve

it from any liability which it may have under this Section 7 except to the extent it has been materially prejudiced by such failure;

and, provided, further, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have

to an indemnified party otherwise than under this Section 7. If any such action shall be brought against an indemnified party, and

it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that

it wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action with counsel reasonably

satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel to

the indemnifying party). After notice from the indemnifying party to the indemnified party of its election to assume the defense of such

action, except as provided herein, the indemnifying party shall not be liable to the indemnified party under Section 7 for any legal

or other expenses subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable costs

of investigation; provided, however, that any indemnified party shall have the right to employ separate counsel in any such action

and to participate in the defense of such action but the fees and expenses of such counsel (other than reasonable costs of investigation)

shall be at the expense of such indemnified party unless (i) the employment thereof has been specifically authorized in writing by

the Company in the case of a claim for indemnification under Section 7(a) or the Representatives in the case of a claim for

indemnification under Section 7(b), (ii) such indemnified party shall have been advised by its counsel that there may be one

or more legal defenses available to it which are different from or additional to those available to the indemnifying party, or (iii) the

indemnifying party has failed to assume the defense of such action and employ counsel reasonably satisfactory to the indemnified party

within a reasonable period of time after notice of the commencement of the action or the indemnifying party does not diligently defend

the action after assumption of the defense, in which case, if such indemnified party notifies the indemnifying party in writing that it

elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume

the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense, to continue to defend) such

action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently incurred

by such indemnified party in connection with the defense of such action; provided, however, that the indemnifying party

shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising

out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of

attorneys at any time for all such indemnified parties (in addition to any local counsel), which firm shall be designated in writing by

the Representatives if the indemnified parties under this Section 7 consist of any Underwriter Indemnified Party or by the Company

if the indemnified parties under this Section 7 consist of any Company Indemnified Parties. Subject to this Section 7(c), the

amount payable by an indemnifying party under Section 7 shall include, but not be limited to, (x) reasonable and documented

legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending

against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any action, investigation, proceeding

or claim, and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written

consent of the indemnified parties, settle or compromise or consent to the entry of judgment with respect to any pending or threatened

action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this Section 7 (whether

or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes

an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party from all liability

arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure

to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party shall be liable

for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent

shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been unreasonably withheld

or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless

any indemnified party from and against any loss or liability by reason of such settlement or judgment. In addition, if at any time an

indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such

indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by this Section 7(c) effected

without its written consent if (i) such settlement is entered into more than forty-five (45) days after receipt by such indemnifying

party of the request for reimbursement, (ii) such indemnifying party shall have received notice of the terms of such settlement at

least thirty (30) days prior to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such

indemnified party in accordance with such request prior to the date of such settlement.

(d)            If

the indemnification provided for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under Section 7(a) or

7(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable or otherwise

incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding

in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the

Company on the one hand and the Underwriters on the other from the offering of the Securities, or (ii) if the allocation provided

by clause (i) of this Section 7(d) is not permitted by applicable law, in such proportion as is appropriate to reflect

not only the relative benefits referred to in clause (i) of this Section 7(d) but also the relative fault of the Company

on the one hand and the Underwriters on the other with respect to the statements, omissions, acts or failures to act which resulted in

such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant

equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other with respect

to such offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Securities purchased

under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received

by the Underwriters with respect to the Securities purchased under this Agreement, in each case as set forth in the table on the cover

page of the Prospectus. The relative fault of the Company on the one hand and the Underwriters on the other shall be determined by

reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission

to state a material fact relates to information supplied by the Company on the one hand or the Underwriters on the other, the intent of

the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission,

act or failure to act; provided that the parties hereto agree that the written information furnished to the Company through the

Representatives by or on behalf of the Underwriters for use in the Registration Statement or the Prospectus, or in any amendment or supplement

thereto, consists solely of the Underwriters’ Information.

(e)            The

Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to Section 7(d) above were

to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations

referred to Section 7(d) above. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense,

liability, action, investigation or proceeding referred to in Section 7(d) above shall be deemed to include, subject to the

limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating,

preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with,

any such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section 7,

no Underwriter shall be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions

received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages which the Underwriter has

otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or alleged

act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of

the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’

obligations to contribute as provided in this Section 7 are several in proportion to their respective underwriting obligations and

not joint.

8.            Termination.

The obligations of the Underwriters hereunder may be terminated by the Representatives, in their absolute discretion by notice given to

the Company prior to delivery of and payment for the Firm Stock, the Common Warrants and the Pre-Funded Warrants if, prior to that time,

any of the events described in Sections 6(j) or 6(l) have occurred or if the Underwriters shall decline to purchase the Firm

Stock, the Common Warrants and the Pre-Funded Warrants for any reason permitted under this Agreement.

9.            Reimbursement

of Underwriters’ Expenses. Notwithstanding anything to the contrary in this Agreement, if (a) this Agreement shall

have been terminated pursuant to Section 8 or 10, (b) the Company shall fail to tender the Securities for delivery to the Underwriters,

or in the case of the Pre-Funded Warrants and accompanying Common Warrants, to the purchasers thereof, if applicable, for any reason not

permitted under this Agreement, (c) the Underwriters shall decline to purchase the Securities for any reason permitted under this

Agreement or (d) the sale of the Securities is not consummated because any condition to the obligations of the Underwriters set forth

herein is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement herein or

to satisfy any condition or to comply with the provisions hereof, then in addition to the payment of amounts in accordance with Section 5,

the Company shall reimburse the Underwriters for the fees and expenses of Underwriters’ counsel and for such other out-of-pocket

expenses as shall have been reasonably incurred and documented by them in connection with this Agreement and the proposed purchase of

the Securities, including, without limitation, travel and lodging expenses of the Underwriters, and upon demand the Company shall pay

the full amount thereof to the Representatives; provided that if this Agreement is terminated pursuant to Section 10 by reason

of the default of one or more Underwriters, the Company shall not be obligated to reimburse any defaulting Underwriter on account of expenses

to the extent incurred by such defaulting Underwriter, provided further that the foregoing shall not limit any reimbursement obligation

of the Company to any non-defaulting Underwriter under this Section 9.

10.            Substitution

of Underwriters. If any Underwriter or Underwriters shall default in its or their obligations to purchase Securities hereunder

on any Closing Date and the aggregate number of Securities which such defaulting Underwriter or Underwriters agreed but failed to purchase

does not exceed ten percent (10%) of the total number of Securities to be purchased by all Underwriters on such Closing Date, the other

Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the Securities which such

defaulting Underwriter or Underwriters agreed but failed to purchase on such Closing Date. If any Underwriter or Underwriters shall so

default and the aggregate number of Securities with respect to which such default or defaults occur is more than ten percent (10%) of

the total number of Securities to be purchased by all Underwriters on such Closing Date and arrangements satisfactory to the Representatives

and the Company for the purchase of such Securities by other persons are not made within forty-eight (48) hours after such default, this

Agreement shall terminate.

If the remaining Underwriters

or substituted Underwriters are required hereby or agree to take up all or part of the Securities of a defaulting Underwriter or Underwriters

on such Closing Date as provided in this Section 10, (i) the Company shall have the right to postpone such Closing Date for

a period of not more than five (5) full business days in order that the Company may effect whatever changes may thereby be made necessary

in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees promptly to file any

amendments to the Registration Statement or supplements to the Prospectus which may thereby be made necessary, and (ii) the respective

numbers of Securities to be purchased by the remaining Underwriters or substituted Underwriters shall be taken as the basis of their underwriting

obligation for all purposes of this Agreement. Nothing herein contained shall relieve any defaulting Underwriter of its liability to the

Company or the other Underwriters for damages occasioned by its default hereunder. Any termination of this Agreement pursuant to this

Section 10 shall be without liability on the part of any non-defaulting Underwriter or the Company, except that the representations,

warranties, covenants, indemnities, agreements and other statements set forth in Section 2, the obligations with respect to expenses

to be paid or reimbursed pursuant to Sections 5 and 9 and the provisions of Section 7 and Sections 11 through 21, inclusive, shall

not terminate and shall remain in full force and effect.

11.            Absence

of Fiduciary Relationship. The Company acknowledges and agrees that:

(a)            each

Underwriter’s responsibility to the Company is solely contractual in nature, the Representatives have been retained solely to act

as underwriters in connection with the sale of the Securities and no fiduciary, advisory or agency relationship between the Company and

the Representatives has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether any

of the Representatives has advised or is advising the Company on other matters;

(b)            the

price of the Securities set forth in this Agreement was established by the Company following discussions and arms-length negotiations

with the Representatives, and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and

conditions of the transactions contemplated by this Agreement;

has been advised that the Representatives and their affiliates are engaged in a broad range of transactions which may involve interests

that differ from those of the Company and that the Representatives have no obligation to disclose such interests and transactions to the

Company by virtue of any fiduciary, advisory or agency relationship; and

(d)            it

waives, to the fullest extent permitted by law, any claims it may have against the Representatives for breach of fiduciary duty or alleged

breach of fiduciary duty and agrees that the Representatives shall have no liability (whether direct or indirect) to the Company in respect

of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders,

employees or creditors of the Company.

12.            Successors;

Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the several Underwriters,

the Company and their respective successors and assigns. Nothing expressed or mentioned in this Agreement is intended or shall be construed

to give any person, other than the persons mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or

in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and provisions hereof being intended

to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations,

warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall also be for the benefit of the Underwriter

Indemnified Parties, and the indemnities of the several Underwriters shall be for the benefit of the Company Indemnified Parties. It is

understood that each Underwriter’s responsibility to the Company is solely contractual in nature and the Underwriters do not owe

the Company, or any other party, any fiduciary duty as a result of this Agreement. No purchaser of any of the Securities from any Underwriter

shall be deemed to be a successor or assign by reason merely of such purchase.

13.            Survival

of Indemnities, Representations, Warranties, etc. The respective indemnities, covenants, agreements, representations,

warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by them respectively,

pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter,

the Company or any person controlling any of them and shall survive delivery of and payment for the Securities. Notwithstanding any termination

of this Agreement, including without limitation any termination pursuant to Section 8 or Section 10, the indemnities, covenants,

agreements, representations, warranties and other statements forth in Sections 2, 5, 7 and 9 and Sections 11 through 21, inclusive, of

this Agreement shall not terminate and shall remain in full force and effect at all times.

14.            Recognition

of the U.S. Special Resolution Regimes.

(a)            In

the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer

from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent

as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were

governed by the laws of the United States or a state of the United States.

(b)            In

the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under

a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to

be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement

were governed by the laws of the United States or a state of the United States.

15.            Notices.

All statements, requests, notices and agreements hereunder shall be in writing, and:

(a)            if

to the Underwriters, shall be delivered or sent by mail, telex, facsimile transmission or email to TD Securities (USA) LLC, 1 Vanderbilt

Avenue, New York, New York 10017, Attention: Head of Equity Capital Markets, with a copy to CIBLegal@tdsecurities.com; and Lake Street

Capital Markets, LLC, 121 South 8th Street, Suite 1000, Minneapolis, Minnesota 55402, Attention: Head of Investment Banking;

(b)            if

to the Company, shall be delivered or sent by mail, telex, facsimile transmission or email to Rapid Micro Biosystems, Inc., 1001

Pawtucket Boulevard West, Suite 280, Lowell, MA 01854, Attention: Chief Financial Officer, email: ***, with

a copy to Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210, Attention: John Egan and Katie Hand, email: jegan@goodwinlaw.com;

khand@goodwinlaw.com.

provided, however, that any notice to an

Underwriter pursuant to Section 7 shall be delivered or sent by mail, or facsimile transmission to such Underwriter at its address

set forth in its acceptance telex to the Representatives, which address will be supplied to any other party hereto by the Representatives

upon request. Any such statements, requests, notices or agreements shall take effect at the time of receipt thereof.

16.            Definition

of Certain Terms. For purposes of this Agreement, (a) “affiliate” has the meaning set forth

in Rule 405 under the Securities Act, (b) “business day” means any day on which the Exchange is open

for trading, (c) “subsidiary” has the meaning set forth in Rule 405 of the Rules and Regulations,

(d) “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted

in accordance with, 12 U.S.C. § 1841(k), (e) “Covered Entity” means any of the following: (i) a

“covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a

“covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a

“covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b), (f) “Default

Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81,

47.2 or 382.1, as applicable, and (g) “U.S. Special Resolution Regime” means each of (i) the Federal

Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer

Protection Act and the regulations promulgated thereunder.

17.            Governing

Law, Jurisdiction, Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance with the laws of the

State of New York, including without limitation Section 5-1401 of the New York General Obligations. The Company irrevocably (a) submits

to the exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York for the purpose of any

suit, action or other proceeding arising out of this Agreement or the transactions contemplated by this Agreement, the Registration Statement

and the Prospectus, (b) agrees that all claims in respect of any such suit, action or proceeding may be heard and determined by any

such court, (c) waives to the fullest extent permitted by applicable law, any immunity from the jurisdiction of any such court or

from any legal process, (d) agrees not to commence any such suit, action or proceeding other than in such courts, and (e) waives,

to the fullest extent permitted by applicable law, any claim that any such suit, action or proceeding is brought in an inconvenient forum.

Each of the parties to this Agreement hereby waives any right to trial by jury in any suit or proceeding arising out of or relating

to this Agreement.

18.            Underwriters’

Information. The parties hereto acknowledge and agree that, for all purposes of this Agreement, the Underwriters’

Information consists solely of the following information in the Prospectus: the statements concerning the Underwriters contained in the

second sentence of the ninth paragraph, the first sentence in the twelfth paragraph and the first sentence of the fourteenth paragraph

under the heading “Underwriting.”

19.            Authority

of the Representatives. In connection with this Agreement, the Representatives will act for and on behalf of the several Underwriters,

and any action taken under this Agreement by the Representatives, will be binding on all the Underwriters.

20.            Partial

Unenforceability. The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall

not affect the validity or enforceability of any other section, paragraph, clause or provision hereof. If any section, paragraph, clause

or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor

changes (and only such minor changes) as are necessary to make it valid and enforceable.

21.            General.

This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous

oral agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine

and neuter genders and the singular and the plural include one another. The section headings in this Agreement are for the convenience

of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may be amended or modified,

and the observance of any term of this Agreement may be waived, only by a writing signed by the Company and the Representatives.

22.            Counterparts.

This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures

thereto and hereto were upon the same instrument. This Agreement may be delivered via facsimile, electronic mail (including pdf or any

electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission

method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

If the foregoing is in accordance

with your understanding please indicate your acceptance of this Agreement by signing in the space provided for that purpose below.

Very truly yours,

RAPID MICRO BIOSYSTEMS, INC.

By:

/s/ Sean Wirtjes

Name: Sean Wirtjes

Title: Chief Financial Officer

Accepted as of

the date first above written:

TD Securities

(USA) LLC

Lake

Street Capital Markets, LLC

Acting on their own behalf

and as Representatives of several

Underwriters listed on Schedule A to this Agreement.

By:

TD SECURITIES (USA) LLC

By:

/s/ Peter Callas

Name:

Peter Callas

Title:

Managing Director

By:

Lake

Street Capital Markets, Llc

By:

/s/ Michael Townley

Name:

Michael Townley

Title:

Head of Investment Banking

SCHEDULE A

Name

Number of Shares

of Firm Stock to

be Purchased

Number of Pre-Funded

Warrants to be

Purchased

Number of

Accompanying Series

A Common Warrants

to be Purchased

Number of

Accompanying

Series B Common

Warrants to be

Purchased

TD Securities (USA) LLC

2,506,700

1,024,100

3,530,800

Lake Street Capital Markets, LLC

1,074,300

438,900

1,513,200

Total

3,581,000

1,463,000

5,044,000

SCHEDULE B

General Use Free Writing Prospectuses

None.

SCHEDULE C

Pricing Information

Firm Stock to be Sold: 3,581,000 shares

Pre-Funded Warrants to be Sold: 1,463,000

Series A Common Warrants to be Sold: 5,044,000

Series B Common Warrants to be Sold: 5,044,000

Exercise Price of Series A Common Warrants:

$1.955 per share

Exercise Price of Series B Common Warrants:

$2.340 per share

Offering Price per Share of Common Stock and accompanying

Series A Common Warrant and Series B Common Warrant: $1.955

Offering Price per Pre-Funded Warrant and accompanying

Series A Common Warrant and Series B Common Warrant: $1.945

Underwriting Discounts and Commissions: 6.00%

Estimated Net Proceeds to the Company (after underwriting discounts

and commissions, but before transaction expenses): $9,254,729

The number of Shares offered in the Concurrent Offering: 71,607

SCHEDULE D

Directors & Officers

1.            Robert

Spignesi

2.            Sean

Wirtjes

3.            Dafni

Bika

4.            Richard

Kollender

5.            Melinda

Litherland

6.            Inese

Lowenstein

7.            Kirk

D. Malloy

8.            Natale

Ricciardi

Exhibit I

Form of Lock-Up Agreement

May [●], 2026

TD Securities

(USA) LLC

Lake Street

Capital Markets, LLC

As Representatives

of the several Underwriters

c/o TD Securities (USA) LLC

1 Vanderbilt Avenue

New York, New York 10017

c/o Lake Street Capital Markets, LLC

121 South 8th Street, Suite 1000

Minneapolis, Minnesota 55402

Re: Rapid Micro Biosystems, Inc. –

Registration Statement on Form S-3 for Shares of Class A Common Stock

Dear Sirs and Madams:

This letter agreement (“Agreement”)

is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) between Rapid

Micro Biosystems, Inc., a Delaware corporation (the “Company”), and TD Securities (USA) LLC (“TD Cowen”)

and Lake Street Capital Markets, LLC (“Lake Street”), as representatives (the “Representatives”) of a group of

underwriters (collectively, the “Underwriters”), to be named therein, and the other parties thereto (if any), relating to

the proposed public offering of shares of the Class A common stock, par value $0.01 per share (the “Common Stock”) of

the Company (the “Offering”).

In order to induce the Underwriters to enter into

the Underwriting Agreement, and in light of the benefits that the Offering will confer upon the undersigned in his, her or its capacity

as a securityholder and/or an officer or director of the Company, and for good and valuable consideration, the receipt and sufficiency

of which are hereby acknowledged, the undersigned agrees with each Underwriter that, during the period beginning on the date hereof through

and including the date that is the 60th day after the date of the Underwriting Agreement (the “Lock-Up Period”),

the undersigned will not, and will not cause or direct any of its affiliates to, without the prior written consent of TD Cowen and Lake

Street, directly or indirectly, (i) offer, sell, assign, transfer, pledge, contract to sell, lend or otherwise dispose of, or publicly

announce the intention to otherwise dispose of, any shares of Common Stock (including, without limitation, Common Stock which may be deemed

to be beneficially owned by the undersigned in accordance with the rules and regulations promulgated under the Securities Exchange

Act of 1934, as amended (the “Exchange Act”) as the same may be amended or supplemented from time to time (such shares, the

“Beneficially Owned Shares”)) or securities convertible into or exercisable or exchangeable for Common Stock, (ii) enter

into, or publicly announce the intention to enter into, any swap, hedge or similar agreement or arrangement (including, without limitation,

the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction

or instrument, however described or defined) that transfers, is designed to transfer or reasonably could be expected to transfer (whether

by the undersigned or someone other than the undersigned) in whole or in part, directly or indirectly, the economic risk of ownership

of the Beneficially Owned Shares or securities convertible into or exercisable or exchangeable for Common Stock, whether now owned or

hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (the

“Prohibited Activity”), or (iii) engage in, or publicly announce the intention to engage in, any short selling of the

Common Stock or securities convertible into or exercisable or exchangeable for Common Stock. The undersigned represents and warrants that

the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement

that is designed to or which reasonably could be expected to lead to or result in any Prohibited Activity during the Lock-Up Period.

If the undersigned is not a natural person, the

undersigned represents and warrants that no single natural person, entity or “group” (within the meaning of Section 13(d)(3) of

the Exchange Act), other than a natural person, entity or “group” (as described above) that has executed an Agreement in substantially

the same form as this Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more

of the voting power, in the undersigned.

The restrictions set forth in the immediately

preceding paragraphs shall not apply to:

(1)            if

the undersigned is a natural person, any transfers made by the undersigned (a) as a bona fide gift to any member of the immediate

family (as defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or members of the

undersigned’s immediate family, (b) by will, other testamentary document or intestate succession upon the death of the undersigned,

(c) as a bona fide gift to a charity or educational institution, or (d) transfers that occur solely by operation of law pursuant

to a qualified domestic order or in connection with a divorce settlement,

(2)            if

the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers or distributions to any

stockholder, partner or member of, or beneficial owner of a similar equity interest in, the undersigned, as the case may be, if, in any

such case, such transfer is not for value,

(3)            if

the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the undersigned

(a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned’s

capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially

all of the undersigned’s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement

or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate

(as defined below) of the undersigned and such transfer is not for value,

(4)            transactions

relating to Common Stock or other securities convertible into or exercisable or exchangeable for Common Stock acquired in open market

transactions after completion of the Offering, provided that no such transaction is required to be, or is, publicly announced (whether

on Form 4, Form 5 or otherwise) during the Lock-Up Period,

(5)            the

entry, by the undersigned, at any time on or after the date of the Underwriting Agreement, of any trading plan providing for the sale

of Common Stock by the undersigned, which trading plan meets the requirements of Rule 10b5-1(c) under the Exchange Act, provided,

however, that such plan does not provide for, or permit, the sale of any Common Stock during the Lock-up Period and, except as required

by applicable securities laws, no public announcement or filing is voluntarily made or required regarding such plan during the Lock-Up

Period,

(6)            any

transfers or dispositions made by the undersigned to satisfy tax withholding obligations pursuant to the Company’s equity incentive

plans or arrangements disclosed in the Prospectus (as defined in the Underwriting Agreement); and

(7) the transfer of shares of Common

Stock under a trading plan pursuant to Rule 10b5-1 under the Exchange Act (a “Trading Plan”) that is existing on the

date hereof which has been provided to TD Cowen and Lake Street or its legal counsel; provided, that, to the extent a public announcement

or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding

such transfer, such announcement or filing shall include a statement that such transfer is in accordance with an established Trading Plan.

provided, however, that in the case of any transfer

described in clause (1), (2) or (3) above, it shall be a condition to the transfer that (A) the transferee executes

and delivers to TD Cowen and Lake Street, acting on behalf of the Underwriters, not later than one business day prior to such transfer,

a written agreement, in substantially the form of this Agreement (it being understood that any references to “immediate family”

in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and not to the immediate

family of the transferee) and otherwise satisfactory in form and substance to TD Cowen and Lake Street, and (B) in the case of any

transfer described in clause (1), (2), (3) or (6) above, no public announcement or filing is voluntarily made regarding such

transfer during the Lock-Up Period and if the undersigned is required to file a report under Section 16(a) of the Exchange Act,

reporting a reduction in beneficial ownership of shares of Common Stock or Beneficially Owned Shares or any securities convertible into

or exercisable or exchangeable for Common Stock or Beneficially Owned Shares during the Lock-Up Period, the undersigned shall include

a statement in such report to the effect that, (A) in the case of any transfer pursuant to clause (1) above, such transfer

is being made as a gift or by will or intestate succession, (B) in the case of any transfer pursuant to clause (2) above,

such transfer is being made to a stockholder, partner or member of, or beneficial owner of a similar equity interest in, the undersigned

and is not a transfer for value, (C) in the case of any transfer pursuant to clause (3) above, such transfer is being made either

(a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned’s

capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially

all of the undersigned’s assets or (b) to another corporation, partnership, limited liability company or other business entity

that is an affiliate of the undersigned and such transfer is not for value, and (D) in the case of a transfer pursuant to clause

(6) above, such transfer is being made to satisfy tax withholding obligations. For purposes of this paragraph, “immediate family”

shall mean a spouse, child, grandchild or other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned;

and “affiliate” shall have the meaning set forth in Rule 405 under the Securities Act of 1933 (the “Securities

Act”).

For avoidance of doubt, nothing in this Agreement

prohibits the undersigned from exercising any options or warrants to purchase Common Stock (which exercises may be effected on a cashless

basis to the extent the instruments representing such options or warrants permit exercises on a cashless basis), it being understood that

any Common Stock issued upon such exercises will be subject to the restrictions of this Agreement and provided, however, that no public

announcement or filing is voluntarily made regarding such exercise during the Lock-Up Period and provided that if the undersigned is required

to file a report under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of such options or warrants

during the Lock-Up Period, the undersigned shall include a statement in such report to the effect that the disposition relates to the

exercise of an option or warrant, as applicable, and that the shares of Common Stock received upon exercise are subject to the restrictions

of this Agreement.

In order to enable this covenant to be enforced,

the undersigned hereby consents to the placing of legends or stop transfer instructions with the Company’s transfer agent with respect

to any Common Stock or securities convertible into or exercisable or exchangeable for Common Stock.

The undersigned further agrees that it will not,

during the Lock-Up Period, make any demand or request for or exercise any right with respect to the registration under the Securities

Act, of any shares of Common Stock or other Beneficially Owned Shares or any securities convertible into or exercisable or exchangeable

for Common Stock or other Beneficially Owned Shares.

The undersigned hereby represents and warrants

that the undersigned has full power and authority to enter into this Agreement and that this Agreement has been duly authorized (if the

undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned.

This Agreement and all authority herein conferred are irrevocable and shall survive the death or incapacity of the undersigned (if a natural

person) and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned.

The undersigned acknowledges and agrees that the

Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned

with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to

the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose

to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the Representatives

and the other Underwriters are not making a recommendation to you to enter into this Agreement and nothing set forth in such disclosures

is intended to suggest that the Representatives or any Underwriter is making such a recommendation.

This Agreement shall be governed by and construed

in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.

This Agreement may be delivered via facsimile,

electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or

www.echosign.com) or other transmission method and any copy so delivered shall be deemed to have been duly and validly delivered and be

valid and effective for all purposes.

If (i) the Company notifies TD Cowen and

Lake Street in writing that it does not intend to proceed with the Offering, (ii) TD Cowen and Lake Street notify the Company in

writing that they do not intend to proceed with the Offering, (iii) the Underwriting Agreement is not executed by May 29, 2026,

or (iv) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated

for any reason prior to payment for and delivery of any Common Stock to be sold thereunder, then this Agreement shall immediately be terminated

and the undersigned shall automatically be released from all of his, her or its obligations under this Agreement. The undersigned acknowledges

and agrees that whether or not any public offering of Common Stock actually occurs depends on a number of factors, including market conditions.

[Signature page follows]

Very truly yours,

(Name of Stockholder - Please Print)

(Signature)

(Name of Signatory if Stockholder is an entity

- Please Print)

(Title of Signatory if Stockholder is an entity

- Please Print)

Address:

Exhibit II

Form of CFO Certificate

[Attached.]

EX-4.1 — EXHIBIT 4.1

EX-4.1

Filename: tm2614922d1_ex4-1.htm · Sequence: 3

Exhibit 4.1

RAPID MICRO BIOSYSTEMS, INC.

WARRANT TO PURCHASE COMMON STOCK

Number of Shares: [_________] (subject to adjustment)

Warrant No. PFW-[ ]

Original Issue Date: May [ ], 2026

Rapid Micro Biosystems, Inc., a Delaware

corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency

of which are hereby acknowledged, [___________] or its registered assigns (the “Holder”) is entitled, subject to the

terms set forth below, to purchase from the Company up to a total of [______] shares of Class A common stock, $0.01 par value per

share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares,

the “Warrant Shares”) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided

in Section 9 herein, the “Exercise Price”) upon surrender of this Warrant to Purchase Common Stock (including

any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time

and from time to time on or after the date hereof (the “Original Issue Date”), subject to the following terms and conditions:

1. Definitions. For purposes of this Warrant,

the following terms shall have the following meanings: (a) “Affiliate” means any Person directly or indirectly

controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the

Securities Act, but only for so long as such control shall continue.

(b) “Commission” means

the United States Securities and Exchange Commission.

means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported

by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade

price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security

is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for

the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency

succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on

any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined

by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the

Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors’

determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for

any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

(d) “Marketable Securities”

means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements

of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the

class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction

(as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized

securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental

Transaction, the Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that

would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior

to the closing of such Fundamental Transaction.

(e) “Principal Trading Market”

means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading,

which, as of the Original Issue Date, shall be the Nasdaq Capital Market.

(f) “Registration Statement”

means the Company’s Registration Statement on Form S-3 (File No 333- 276081), as filed with the Commission on December 15,

2023 and declared effective on December 26, 2023.

(g) “Securities Act” means

the Securities Act of 1933, as amended.

(h) “Standard Settlement Period”

means the standard settlement period, expressed in a number of Trading Days, for the Company’s primary trading market or quotation

system with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original

Issue Date is “T+1”.

(h) “Trading Day” means

any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, “Trading

Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on

which banking institutions in New York City are authorized or required by law or other governmental action to close.

(i) “Transfer Agent” means

Computershare Trust Company, N.A., the Company’s transfer agent and registrar for the Common Stock, and any successor appointed

in such capacity.

2. Issuance of Securities; Registration of

Warrants. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original

Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant

to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on

the Original Issue Date, the Warrant Shares, are not “restricted securities” under Rule 144 promulgated under the Securities

Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant

Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to

which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the

absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual

notice to the contrary.

3. Registration of Transfers. Subject to

compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or

any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if

any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such

new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee,

and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder.

The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and

obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer

Agent to, prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 3. Until due presentment

for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company

shall not be affected by any notice to the contrary.

4. Exercise and Duration of Warrants.

(a) All or any part of this Warrant shall

be exercisable by the registered Holder in the manner set forth in Section 10 at any time and from time to time on or after the Original

Issue Date, and such rights shall not expire.

(b) The Holder may exercise this

Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the “Exercise

Notice”), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in

accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not be required to deliver

the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same

effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number

of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of

the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares

available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

5. Delivery of Warrant Shares.

(a) Upon exercise of this Warrant, the Company

shall, or shall cause the Transfer Agent to, promptly (but in no event later than the number of Trading Days comprising the Standard Settlement

Period following the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the

Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with The Depository Trust Company

(“DTC”) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the

Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability,

issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s

share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant

to such exercise. The Holder, or any natural person or legal entity (each, a “Person”) so designated by the Holder

to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective

of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing

such Warrant Shares, as the case may be.

(b) If the Company fails to deliver to the

Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to Section 5(a) or

fails to credit the Holder’s DTC account for such number of Warrant Shares to which the Holder is entitled within the Standard Settlement

Period following the Exercise Date, and if after such Standard Settlement Period and prior to the receipt of such Warrant Shares, the

Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder

of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall,

within three (3) Trading Days after the Holder’s request promptly honor its obligation to deliver to the Holder a certificate

or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder’s

total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In less the product

of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock

on the Exercise Date.

to Section 5(b), the Company’s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms

hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction

by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any

Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged

breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or

any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in

connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder’s right to pursue

any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or

injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as

required pursuant to the terms hereof.

6. Charges, Taxes and Expenses. Issuance

and delivery of shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer

tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such

shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required

to pay any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a

name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise

as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

7. Replacement of Warrant. If this Warrant

is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation

hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the

Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if

requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations

and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result

of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s

obligation to issue the New Warrant.

8. Reservation of Warrant Shares. The Company

covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized

but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this

Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire

Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the

adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon

issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued

and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of

Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities

exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without

the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant

is outstanding.

9. Certain Adjustments. The Exercise Price

and number of Warrant Shares issuable upon exercise of this Warrant (the “Number of Warrant Shares”) are subject to

adjustment from time to time as set forth in this Section 9.

(a) Stock Dividends and Splits. If

the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock that is payable in shares

of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines

its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares

of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied

by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator

of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause

(i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to

receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully

paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record

date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such

dividends. Any adjustment pursuant to clause (ii), (iii) or (iv) of this paragraph shall become effective immediately after

the effective date of such subdivision, combination or issuance.

(b) Pro Rata Distributions. If the

Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences

of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights

or warrants to subscribe for or purchase any security (including Common Stock), or (iv) cash or any other asset (in each case, a

“Distribution”), other than a reclassification as to which Section 9(c) applies, then in each such case,

the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if

the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations

on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before

the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of

Common Stock are to be determined for the participation in such Distribution; provided, however, to the extent that the

Holder’s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in

Section 11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial

ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance

for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder

exceeding the ownership limitation set forth in Section 11(a) hereof.

at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another

Person, in which the Company is not the surviving entity, (ii) the Company effects any sale to another Person of all or substantially

all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether

by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital

stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates

a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off

or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital

stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain,

in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects

any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted

into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock

covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”), then following such Fundamental

Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or

property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior

to such Fundamental Transaction, the holder of the Number of Warrant Shares without regard to any limitations on exercise contained herein

(in the case of clause (iii) above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the “Alternate

Consideration”). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or

the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company

provides for the simultaneous “cashless exercise” of this Warrant pursuant to Section 10 below or (ii) prior to

or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser

of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the

foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph

(c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing,

in the event of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of

Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised

in full in a “cashless exercise” pursuant to Section 10 below effective immediately prior to and contingent upon the

consummation of such Fundamental Transaction.

(d) Exercise Price. Simultaneously

with any adjustment to the Number of Warrant Shares pursuant to Section 9 the Exercise Price shall be increased or decreased proportionately,

so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall

be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event

may the Exercise Price be adjusted below the par value of the Common Stock then in effect.

(e) Calculations. All calculations

under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest whole share, as applicable.

(f) Notice of Adjustments. Upon the

occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder,

promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth

such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities

issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail

the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate

to the Holder and to the Company’s transfer agent.

(g) Notice of Corporate Events. If,

while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property

in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital

stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder

approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs

of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the

Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective

date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided,

however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required

to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any

agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than

a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be

deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction

at least ten (10) days prior to the date such Fundamental Transaction is consummated.

10. Cashless Exercise. Notwithstanding

anything contained herein to the contrary, this Warrant may only be exercised through a “cashless exercise.” Upon exercise,

the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of

the Securities Act as determined as follows:

X = Y [(A-B)/A]

where:

“X” equals the number of Warrant Shares to be issued to

the Holder;

“Y” equals the total number of Warrant Shares with respect

to which this Warrant is then being exercised;

“A” equals the Closing Sale Price per share of Common Stock

as of the Trading Day on the date immediately preceding the Exercise Date; and

“B” equals the Exercise Price per Warrant Share then in

effect on the Exercise Date.

For purposes of Rule 144 promulgated under

the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a “cashless exercise”

transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have

commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment

is proper at the time of such exercise).

In no event will the exercise of this Warrant be settled in cash.

11. Limitations on Exercise.

(a) Notwithstanding anything to the contrary

contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant

(i) if immediately prior to the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock

would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act, beneficially own an aggregate

number of shares of Common Stock greater than [4.5] [4.99] [9.99] % (the “Maximum Percentage”) of the total number

of issued and outstanding shares of Common Stock of the Company without taking into account any Warrant Shares, or (ii) to the extent

that immediately following the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would

be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act, would beneficially own in excess of

the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares

of Common Stock. Any portion of an exercise that would result in the issuance of shares in excess of the Maximum Percentage shall be treated

as null and void ab initio. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder

may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or

Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by

the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding.

Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail

to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall

be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since

the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may

from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such

notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company.

For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the

Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s

for purposes of Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this

Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be

issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise

or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting

power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common

Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible

into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation

on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates

and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of

the Exchange Act. For purposes of clarity, the Warrant Shares issuable pursuant to the terms of this Warrant in excess of the Maximum

Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) of

the Exchange Act or Rule 16a-1(a)(1) promulgated under the Exchange Act.

(b) This Section 11 shall not restrict

the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or

other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of

this Warrant.

12. No Fractional Shares. No fractional

Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be

issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder

in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.

13. Notices. Any and all notices or other

communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given

and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed email prior

to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication

is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day,

(iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business

day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses

and e-mail addresses for such communications shall be:

If to the Company:

Rapid Micro Biosystems, Inc.

25 Hartwell Avenue

Lexington, MA 02421

Attention: Chief Executive Officer

Telephone: (978) 349-3200

Email: [___]

If to the Holder, to its address or e-mail address set forth herein

or on the books and records of the Company.

Or, in each of the above instances, to such other

address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days

prior to the effectiveness of such change.

14. Warrant Agent. The Company shall initially

serve as warrant agent under this Warrant. Upon ten (10) days’ notice to the Holder, the Company may appoint a new warrant

agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation

to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers

substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without

any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first

class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

15. Miscellaneous.

(a) No Rights as a Stockholder. The

Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed

the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the

Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any

right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,

consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or

otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise

of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase

any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted

by the Company or by creditors of the Company.

(b) Authorized Shares. Except and

to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its

certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue

or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this

Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may

be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality

of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such

exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that

the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (iii) use

commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction

thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company

without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding

on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence,

nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy

or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors

and assigns.

(d) Amendment and Waiver. Except as

otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company

and the Holder; provided that, Section 11(a) may not be modified or amended.

(e) Acceptance. Receipt of this Warrant by the Holder shall

constitute acceptance of and agreement to all of the terms and conditions contained herein.

(f) Governing Law; Jurisdiction. ALL

QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND

ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE

COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF

NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED

HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES,

AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH

COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN

ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF

DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT

SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY

MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

(g) Headings. The headings herein

are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

(h) Severability. In case any one

or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining

terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt

in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so

agreeing, shall incorporate such substitute provision in this Warrant.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly

executed by its authorized officer as of the date first indicated above.

RAPID MICRO BIOSYSTEMS, INC.

By:

Name:

Robert Spignesi

Title:

President and Chief Executive Officer

SCHEDULE 1

FORM OF EXERCISE NOTICE

[To be executed by the Holder to purchase shares

of Common Stock under the Warrant]

Ladies and Gentlemen: (1) The undersigned is the Holder of Warrant

No. ___ (the “Warrant”) issued by Rapid Micro Biosystems, Inc., a Delaware corporation (the “Company”).

Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.

(2)

The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.

(3)

The Holder intends that payment of the Exercise Price shall be made as a “Cashless Exercise” under Section 10 of the Warrant.

(4)

Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:

(5)

By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.

Dated:

Name of Holder:

By:

Name:

Title:

(Signature must conform in all respects to name of Holder as specified

on the face of the Warrant)

EX-4.2 — EXHIBIT 4.2

EX-4.2

Filename: tm2614922d1_ex4-2.htm · Sequence: 4

Exhibit 4.2

RAPID MICRO BIOSYSTEMS, INC.

WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED

WARRANTS

Number of Shares: [_________] (subject to adjustment)

Warrant No. CW-[___]

Original Issue Date: May [___], 2026

Rapid Micro Biosystems, Inc., a Delaware

corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency

of which are hereby acknowledged, [___________] or its registered assigns (the “Holder”) is entitled, subject to the

terms set forth below, to purchase from the Company up to a total of [______] shares of Class A common stock, $0.01 par value per

share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares,

the “Warrant Shares”) at an exercise price per share equal to $2.07 (the “Exercise Price”), in each

case as adjusted from time to time as provided in Section 9, upon surrender of this Warrant to Purchase Common Stock or Pre-Funded

Warrants (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”)

at any time and from time to time on or after [_], 20261 (the “Initial Exercise Date”) and on or prior

to 5:00 p.m. (New York City time) on May, [_], 2027 (the “Termination Date”) but not thereafter, subject to the

following terms and conditions: